

WEBVTT

NOTE duration:"01:08:27"

NOTE recognizability:0.789

NOTE language:en-us

NOTE Confidence: 0.8370638333333333

00:00:00.000 --> 00:00:03.560 OK. Good afternoon, everybody.

NOTE Confidence: 0.8370638333333333

00:00:03.560 --> 00:00:07.688 Welcome to our. Next, ash review.

NOTE Confidence: 0.8370638333333333

00:00:07.690 --> 00:00:11.855 This is a review on cellular therapies,

NOTE Confidence: 0.8370638333333333

00:00:11.860 --> 00:00:13.960 and we have, I think,

NOTE Confidence: 0.8370638333333333

00:00:13.960 --> 00:00:15.610 2 exciting presentations

NOTE Confidence: 0.8370638333333333

00:00:15.610 --> 00:00:17.810 for you this afternoon.

NOTE Confidence: 0.8370638333333333

00:00:17.810 --> 00:00:20.008 The first is going to be with

NOTE Confidence: 0.8370638333333333

00:00:20.008 --> 00:00:21.418 Doctor Iris Isufi. Dr.

NOTE Confidence: 0.8370638333333333

00:00:21.418 --> 00:00:24.226 Isufi is associate professor in the

NOTE Confidence: 0.8370638333333333

00:00:24.226 --> 00:00:26.770 Department of Medicine and Hematology

NOTE Confidence: 0.8370638333333333

00:00:26.770 --> 00:00:30.095 in the Yale Cancer Center and the

NOTE Confidence: 0.8370638333333333

00:00:30.095 --> 00:00:33.268 director of our Cell Therapy research

NOTE Confidence: 0.8370638333333333

00:00:33.268 --> 00:00:36.562 team and our Clinical Care T.

NOTE Confidence: 0.8370638333333333

00:00:36.570 --> 00:00:39.150 Program and she's gonna talk to
NOTE Confidence: 0.8370638333333333

00:00:39.150 --> 00:00:41.773 you about some advances in cell
NOTE Confidence: 0.8370638333333333

00:00:41.773 --> 00:00:44.233 therapy at the latest ash meeting.
NOTE Confidence: 0.8370638333333333

00:00:44.240 --> 00:00:46.766 So, Doctor Suffi, take it away.
NOTE Confidence: 0.861653135

00:00:49.150 --> 00:00:51.358 Thank you Stuart. I'm gonna share my screen.
NOTE Confidence: 0.8588443

00:01:00.170 --> 00:01:02.250 Before you start, can I just
NOTE Confidence: 0.8588443

00:01:02.250 --> 00:01:04.020 remind everybody if you'd like
NOTE Confidence: 0.911925422307692

00:01:04.096 --> 00:01:06.384 to submit questions, there will
NOTE Confidence: 0.911925422307692

00:01:06.384 --> 00:01:09.156 be a question and answer period.
NOTE Confidence: 0.911925422307692

00:01:09.160 --> 00:01:10.378 Possibly between the
NOTE Confidence: 0.911925422307692

00:01:10.378 --> 00:01:12.408 presentations and at the end,
NOTE Confidence: 0.911925422307692

00:01:12.410 --> 00:01:14.885 but you can submit questions
NOTE Confidence: 0.911925422307692

00:01:14.885 --> 00:01:18.625 through the chat or Q&A during the
NOTE Confidence: 0.911925422307692

00:01:18.625 --> 00:01:21.550 talk and we'll possibly answer
NOTE Confidence: 0.911925422307692

00:01:21.550 --> 00:01:24.690 them during or during during the
NOTE Confidence: 0.911925422307692

00:01:24.690 --> 00:01:27.590 talks or at the end. OK.

NOTE Confidence: 0.822846726666667
00:01:29.610 --> 00:01:31.608 Thanks. So I'll take welcome everyone.
NOTE Confidence: 0.822846726666667
00:01:31.610 --> 00:01:35.082 I'll take the first half of the session
NOTE Confidence: 0.822846726666667
00:01:35.082 --> 00:01:38.940 just to present some of the ash data
NOTE Confidence: 0.822846726666667
00:01:38.940 --> 00:01:42.822 on cell therapies and I know this
NOTE Confidence: 0.822846726666667
00:01:42.822 --> 00:01:45.774 was talked about that the myeloma.
NOTE Confidence: 0.822846726666667
00:01:45.780 --> 00:01:49.280 View as well, but today I'll focus
NOTE Confidence: 0.822846726666667
00:01:49.280 --> 00:01:52.449 particularly on non Hodgkin lymphomas
NOTE Confidence: 0.822846726666667
00:01:52.450 --> 00:01:59.070 and some also exciting data on AL.
NOTE Confidence: 0.822846726666667
00:01:59.070 --> 00:02:04.350 These are my disclosures. So the 1st.
NOTE Confidence: 0.796655256
00:02:07.590 --> 00:02:10.294 Presentation, the first abstract
NOTE Confidence: 0.796655256
00:02:10.294 --> 00:02:13.286 that I wanted to present is abstract
NOTE Confidence: 0.796655256
00:02:13.290 --> 00:02:16.290 655 that's looking at Lysol cell,
NOTE Confidence: 0.796655256
00:02:16.290 --> 00:02:21.462 Lysol catagen, mariluz cell and this
NOTE Confidence: 0.796655256
00:02:21.462 --> 00:02:25.583 is a cellular therapy product that is
NOTE Confidence: 0.796655256
00:02:25.583 --> 00:02:29.034 different from the prior ones on the
NOTE Confidence: 0.796655256

00:02:29.034 --> 00:02:32.029 market because it has a defined CD4
NOTE Confidence: 0.796655256

00:02:32.029 --> 00:02:35.132 to CD8 ratio and this has already been
NOTE Confidence: 0.796655256

00:02:35.132 --> 00:02:37.496 approved in the third line setting.
NOTE Confidence: 0.796655256

00:02:37.500 --> 00:02:39.999 And more recently also in the second
NOTE Confidence: 0.796655256

00:02:39.999 --> 00:02:41.947 line setting for diffuse large
NOTE Confidence: 0.796655256

00:02:41.947 --> 00:02:44.880 B cell lymphoma, so.
NOTE Confidence: 0.796655256

00:02:44.880 --> 00:02:47.495 Here they presented their primary
NOTE Confidence: 0.796655256

00:02:47.495 --> 00:02:50.204 analysis of the randomized phase
NOTE Confidence: 0.796655256

00:02:50.204 --> 00:02:53.039 three transform study where lyso
NOTE Confidence: 0.796655256

00:02:53.039 --> 00:02:57.027 cell was compared to standard of care
NOTE Confidence: 0.796655256

00:02:57.027 --> 00:02:59.227 with salvage chemotherapy alone,
NOTE Confidence: 0.796655256

00:02:59.230 --> 00:03:02.170 so patients had a good performance status.
NOTE Confidence: 0.796655256

00:03:02.170 --> 00:03:07.202 The ones that were randomized to the
NOTE Confidence: 0.796655256

00:03:07.202 --> 00:03:10.730 standard of care arm who had relapsed.
NOTE Confidence: 0.796655256

00:03:10.730 --> 00:03:13.700 Um were randomized to receive 3
NOTE Confidence: 0.796655256

00:03:13.700 --> 00:03:15.680 cycles of chemo immunotherapy.

NOTE Confidence: 0.796655256

00:03:15.680 --> 00:03:17.490 These were high risk patients.

NOTE Confidence: 0.796655256

00:03:17.490 --> 00:03:19.686 They were patients who were either

NOTE Confidence: 0.796655256

00:03:19.686 --> 00:03:21.874 primary refractory to their first line

NOTE Confidence: 0.796655256

00:03:21.874 --> 00:03:23.854 or patients who had relapsed within

NOTE Confidence: 0.796655256

00:03:23.854 --> 00:03:26.058 12 months of their initial therapy.

NOTE Confidence: 0.796655256

00:03:26.060 --> 00:03:28.034 So they took this highest risk group

NOTE Confidence: 0.796655256

00:03:28.034 --> 00:03:30.299 to compare it to stem cell transplant.

NOTE Confidence: 0.796655256

00:03:30.300 --> 00:03:32.922 And so the patients who received

NOTE Confidence: 0.796655256

00:03:32.922 --> 00:03:34.670 salvage chemotherapy and achieved

NOTE Confidence: 0.796655256

00:03:34.743 --> 00:03:37.389 either a complete or a good partial

NOTE Confidence: 0.796655256

00:03:37.389 --> 00:03:39.598 response proceeded to high dose

NOTE Confidence: 0.796655256

00:03:39.598 --> 00:03:41.110 chemotherapy and autologous.

NOTE Confidence: 0.796655256

00:03:41.110 --> 00:03:44.314 Them self rescue a typically with

NOTE Confidence: 0.796655256

00:03:44.314 --> 00:03:47.070 a beam regimen and then.

NOTE Confidence: 0.796655256

00:03:47.070 --> 00:03:49.667 The other arm was randomized to receive

NOTE Confidence: 0.796655256

00:03:49.667 --> 00:03:52.498 lysis cell and so they underwent
NOTE Confidence: 0.796655256

00:03:52.498 --> 00:03:54.145 lymphodepletion with fludarabine
NOTE Confidence: 0.796655256

00:03:54.145 --> 00:03:56.789 and cyclophosphamide and they were
NOTE Confidence: 0.796655256

00:03:56.789 --> 00:03:59.386 allowed to get some bridging if their
NOTE Confidence: 0.796655256

00:03:59.386 --> 00:04:01.470 disease was rapidly progressing.
NOTE Confidence: 0.796655256

00:04:01.470 --> 00:04:02.140 Importantly,
NOTE Confidence: 0.796655256

00:04:02.140 --> 00:04:04.150 in this trial,
NOTE Confidence: 0.796655256

00:04:04.150 --> 00:04:06.880 crossover was allowed for patients
NOTE Confidence: 0.796655256

00:04:06.880 --> 00:04:10.075 who received standard of care and
NOTE Confidence: 0.796655256

00:04:10.075 --> 00:04:13.330 were not deemed to be good candidates
NOTE Confidence: 0.796655256

00:04:13.330 --> 00:04:16.088 for autologous stem cell transplant.
NOTE Confidence: 0.796655256

00:04:16.090 --> 00:04:17.263 For multiple reasons.
NOTE Confidence: 0.796655256

00:04:17.263 --> 00:04:20.000 So they crossed over and the primary
NOTE Confidence: 0.796655256

00:04:20.071 --> 00:04:22.333 endpoint was event free survival and
NOTE Confidence: 0.796655256

00:04:22.333 --> 00:04:25.266 then they looked at complete response rates,
NOTE Confidence: 0.796655256

00:04:25.266 --> 00:04:27.626 progression free and overall survival.

NOTE Confidence: 0.796655256

00:04:27.630 --> 00:04:31.214 They do have now a 17.5 month follow up.

NOTE Confidence: 0.796655256

00:04:31.214 --> 00:04:33.680 And you know that's important because

NOTE Confidence: 0.796655256

00:04:33.751 --> 00:04:36.481 we know that the majority of these

NOTE Confidence: 0.796655256

00:04:36.481 --> 00:04:38.711 patients with primary refractory or

NOTE Confidence: 0.796655256

00:04:38.711 --> 00:04:41.181 early relapse disease will again

NOTE Confidence: 0.796655256

00:04:41.181 --> 00:04:43.088 relapse within typically within

NOTE Confidence: 0.796655256

00:04:43.088 --> 00:04:45.596 the first year of of salvage.

NOTE Confidence: 0.796655256

00:04:45.600 --> 00:04:46.400 So, uh,

NOTE Confidence: 0.796655256

00:04:46.400 --> 00:04:49.600 with that median follow-up you can see here,

NOTE Confidence: 0.796655256

00:04:49.600 --> 00:04:51.620 there was a significant improvement

NOTE Confidence: 0.796655256

00:04:51.620 --> 00:04:54.105 in the event free survival where

NOTE Confidence: 0.796655256

00:04:54.105 --> 00:04:56.487 the median event free survival was

NOTE Confidence: 0.796655256

00:04:56.487 --> 00:04:58.444 actually not reached compared to

NOTE Confidence: 0.796655256

00:04:58.444 --> 00:05:00.526 a median event free survival of

NOTE Confidence: 0.796655256

00:05:00.526 --> 00:05:02.326 only 2.4 months in.

NOTE Confidence: 0.796655256

00:05:02.326 --> 00:05:05.218 The standard of care arm with
NOTE Confidence: 0.796655256

00:05:05.218 --> 00:05:08.184 stem cell transplant with a with
NOTE Confidence: 0.796655256

00:05:08.184 --> 00:05:13.220 a hazard ratio of 0.35.
NOTE Confidence: 0.796655256

00:05:13.220 --> 00:05:15.719 And this was.
NOTE Confidence: 0.796655256

00:05:15.720 --> 00:05:17.480 For a self therapy trial,
NOTE Confidence: 0.796655256

00:05:17.480 --> 00:05:19.664 relatively large trial
NOTE Confidence: 0.796655256

00:05:19.664 --> 00:05:22.212 with about 184 patients,
NOTE Confidence: 0.796655256

00:05:22.212 --> 00:05:24.396 92 on each arm.
NOTE Confidence: 0.796655256

00:05:24.400 --> 00:05:28.024 So you can see here that for their
NOTE Confidence: 0.796655256

00:05:28.024 --> 00:05:30.987 secondary endpoints there is also
NOTE Confidence: 0.796655256

00:05:30.987 --> 00:05:32.892 statistically significant complete
NOTE Confidence: 0.796655256

00:05:32.892 --> 00:05:36.042 response rate of 68% compared to
NOTE Confidence: 0.796655256

00:05:36.042 --> 00:05:39.170 40% in the standard of care arm and
NOTE Confidence: 0.796655256

00:05:39.256 --> 00:05:41.916 an improvement in progression free
NOTE Confidence: 0.796655256

00:05:41.916 --> 00:05:45.748 survival that was not reached for the cell.
NOTE Confidence: 0.796655256

00:05:45.750 --> 00:05:48.221 Therapy group versus only 6.2 months in

NOTE Confidence: 0.796655256

00:05:48.221 --> 00:05:51.150 the standard of care arm for patients

NOTE Confidence: 0.796655256

00:05:51.150 --> 00:05:53.400 who received chemotherapy and transplant.

NOTE Confidence: 0.796655256

00:05:53.400 --> 00:05:54.670 And importantly,

NOTE Confidence: 0.796655256

00:05:54.670 --> 00:05:58.480 despite 67% of patients at crossing

NOTE Confidence: 0.796655256

00:05:58.480 --> 00:06:01.798 over from the transplant arm,

NOTE Confidence: 0.796655256

00:06:01.800 --> 00:06:04.887 the chemotherapy arm to receive Lisa cell,

NOTE Confidence: 0.796655256

00:06:04.890 --> 00:06:05.552 there was,

NOTE Confidence: 0.796655256

00:06:05.552 --> 00:06:06.214 you know,

NOTE Confidence: 0.796655256

00:06:06.214 --> 00:06:08.200 there still seem to be a

NOTE Confidence: 0.830955749

00:06:08.277 --> 00:06:11.235 trend favoring overall survival in patients

NOTE Confidence: 0.830955749

00:06:11.235 --> 00:06:14.160 who received lisa cell where overall

NOTE Confidence: 0.830955749

00:06:14.160 --> 00:06:17.010 survival was not reached versus about

NOTE Confidence: 0.830955749

00:06:17.010 --> 00:06:20.230 30 months in the standard of care arm.

NOTE Confidence: 0.830955749

00:06:20.230 --> 00:06:23.902 So this primary analysis with almost

NOTE Confidence: 0.830955749

00:06:23.902 --> 00:06:26.735 two year of follow-up confirmed

NOTE Confidence: 0.830955749

00:06:26.735 --> 00:06:28.275 the significant clinical benefit
NOTE Confidence: 0.830955749

00:06:28.275 --> 00:06:31.037 of Lisa cell over the standard of
NOTE Confidence: 0.830955749

00:06:31.037 --> 00:06:33.347 care and given these very meaningful
NOTE Confidence: 0.830955749

00:06:33.347 --> 00:06:35.630 improvements in complete response rates,
NOTE Confidence: 0.830955749

00:06:35.630 --> 00:06:39.088 event free and progression free survival this
NOTE Confidence: 0.830955749

00:06:39.088 --> 00:06:41.874 and and a trend towards overall survival.
NOTE Confidence: 0.830955749

00:06:41.880 --> 00:06:44.974 This has now been approved and is
NOTE Confidence: 0.830955749

00:06:44.974 --> 00:06:48.023 considered the standard of care in the
NOTE Confidence: 0.830955749

00:06:48.023 --> 00:06:50.489 second line for patients with primary.
NOTE Confidence: 0.830955749

00:06:50.490 --> 00:06:53.460 Refractory or early relapsed lymphoma
NOTE Confidence: 0.830955749

00:06:53.460 --> 00:06:56.912 and there is another product on
NOTE Confidence: 0.830955749

00:06:56.912 --> 00:06:59.621 the market but this was the one
NOTE Confidence: 0.830955749

00:06:59.621 --> 00:07:02.558 that had the the updated at ASH.
NOTE Confidence: 0.830955749

00:07:02.560 --> 00:07:06.610 At the next one that I was also interested
NOTE Confidence: 0.830955749

00:07:06.610 --> 00:07:10.196 in is abstract 154 where they looked
NOTE Confidence: 0.830955749

00:07:10.196 --> 00:07:12.616 at really aggressive lymphomas that

NOTE Confidence: 0.830955749

00:07:12.616 --> 00:07:15.624 are high grade with Mick and BCL 2

NOTE Confidence: 0.830955749

00:07:15.624 --> 00:07:18.418 plus or minus BCL 6 rearrangements.

NOTE Confidence: 0.830955749

00:07:18.420 --> 00:07:20.828 So the so-called double or triple hit

NOTE Confidence: 0.830955749

00:07:20.828 --> 00:07:22.741 lymphomas and also double expressor

NOTE Confidence: 0.830955749

00:07:22.741 --> 00:07:24.365 lymphomas with dual overexpression

NOTE Confidence: 0.830955749

00:07:24.365 --> 00:07:26.300 of MYC and BCL two.

NOTE Confidence: 0.830955749

00:07:26.300 --> 00:07:29.380 And we know that those are very

NOTE Confidence: 0.830955749

00:07:29.380 --> 00:07:31.275 inferior responses to frontline

NOTE Confidence: 0.830955749

00:07:31.275 --> 00:07:33.700 and later lines of chemotherapy.

NOTE Confidence: 0.830955749

00:07:33.700 --> 00:07:35.955 They have very poor outcomes

NOTE Confidence: 0.830955749

00:07:35.955 --> 00:07:37.759 with stem cell transplantation.

NOTE Confidence: 0.830955749

00:07:37.760 --> 00:07:40.870 There have already been some

NOTE Confidence: 0.830955749

00:07:40.870 --> 00:07:43.327 presentations in terms of the role of

NOTE Confidence: 0.830955749

00:07:43.327 --> 00:07:45.710 cartee for this patient population,

NOTE Confidence: 0.830955749

00:07:45.710 --> 00:07:48.842 which has led to similar overall

NOTE Confidence: 0.830955749

00:07:48.842 --> 00:07:49.886 response rates.
NOTE Confidence: 0.830955749

00:07:49.890 --> 00:07:50.306 However,
NOTE Confidence: 0.830955749

00:07:50.306 --> 00:07:51.554 until this abstract,
NOTE Confidence: 0.830955749

00:07:51.554 --> 00:07:54.511 there had not been any data or
NOTE Confidence: 0.830955749

00:07:54.511 --> 00:07:56.791 update on the duration of response
NOTE Confidence: 0.830955749

00:07:56.791 --> 00:08:00.287 for these high risk groups and so
NOTE Confidence: 0.830955749

00:08:00.287 --> 00:08:01.997 this multicenter retrospective
NOTE Confidence: 0.830955749

00:08:01.997 --> 00:08:03.707 analysis evaluated survival.
NOTE Confidence: 0.830955749

00:08:03.710 --> 00:08:06.422 Outcomes with Carti and also what
NOTE Confidence: 0.830955749

00:08:06.422 --> 00:08:08.830 happened to patients who produced
NOTE Confidence: 0.830955749

00:08:08.830 --> 00:08:11.920 double hit lymphoma or dual overexpress
NOTE Confidence: 0.830955749

00:08:11.920 --> 00:08:14.479 or who progressed after court.
NOTE Confidence: 0.830955749

00:08:14.480 --> 00:08:16.960 And there was a large group of patients,
NOTE Confidence: 0.830955749

00:08:16.960 --> 00:08:18.884 they looked at 408,
NOTE Confidence: 0.830955749

00:08:18.884 --> 00:08:21.770 eighty of which had double hit
NOTE Confidence: 0.830955749

00:08:21.871 --> 00:08:23.952 and 328 non double hit.

NOTE Confidence: 0.830955749

00:08:23.952 --> 00:08:26.640 Some of them received access cells,

NOTE Confidence: 0.830955749

00:08:26.640 --> 00:08:29.304 some Tessa cell and a minority

NOTE Confidence: 0.830955749

00:08:29.304 --> 00:08:32.134 received lica cell and the clinical

NOTE Confidence: 0.830955749

00:08:32.134 --> 00:08:34.624 characteristics were similar between the

NOTE Confidence: 0.830955749

00:08:34.624 --> 00:08:37.819 double hit and the non double hit group.

NOTE Confidence: 0.830955749

00:08:37.820 --> 00:08:40.070 So the median follow-up was also

NOTE Confidence: 0.830955749

00:08:40.070 --> 00:08:42.626 about 18 months for from Carty

NOTE Confidence: 0.830955749

00:08:42.626 --> 00:08:44.096 for surviving patients.

NOTE Confidence: 0.830955749

00:08:44.100 --> 00:08:46.540 So relatively long follow up.

NOTE Confidence: 0.830955749

00:08:46.540 --> 00:08:49.330 And what?

NOTE Confidence: 0.830955749

00:08:49.330 --> 00:08:55.373 What they saw actually was that sorry

NOTE Confidence: 0.830955749

00:08:55.373 --> 00:08:58.194 was that patients did very well or

NOTE Confidence: 0.830955749

00:08:58.194 --> 00:09:01.328 whether they had double hits or dual

NOTE Confidence: 0.830955749

00:09:01.328 --> 00:09:03.124 overexpress or lymphoma compared

NOTE Confidence: 0.830955749

00:09:03.124 --> 00:09:05.709 to other subtypes of lymphoma.

NOTE Confidence: 0.830955749

00:09:05.710 --> 00:09:08.524 In terms of their progression free survival,
NOTE Confidence: 0.830955749

00:09:08.530 --> 00:09:11.806 overall response rates were no different,
NOTE Confidence: 0.830955749

00:09:11.810 --> 00:09:13.718 no statistically significant in
NOTE Confidence: 0.830955749

00:09:13.718 --> 00:09:17.638 the order of 65 to 70% complete
NOTE Confidence: 0.830955749

00:09:17.638 --> 00:09:19.504 response rates also.
NOTE Confidence: 0.830955749

00:09:19.510 --> 00:09:20.650 About 50%,
NOTE Confidence: 0.830955749

00:09:20.650 --> 00:09:24.640 which is what we expect with the
NOTE Confidence: 0.830955749

00:09:24.640 --> 00:09:26.392 run-of-the-mill diffuse large
NOTE Confidence: 0.830955749

00:09:26.392 --> 00:09:28.728 B cell lymphoma and.
NOTE Confidence: 0.830955749

00:09:28.730 --> 00:09:30.968 The median all overall survival was
NOTE Confidence: 0.830955749

00:09:30.968 --> 00:09:33.118 not reached actually for the double
NOTE Confidence: 0.830955749

00:09:33.118 --> 00:09:35.502 hit group versus 21 months in the non
NOTE Confidence: 0.830955749

00:09:35.568 --> 00:09:40.030 double hit and not statistically significant.
NOTE Confidence: 0.830955749

00:09:40.030 --> 00:09:40.990 However,
NOTE Confidence: 0.830955749

00:09:40.990 --> 00:09:41.648 importantly,
NOTE Confidence: 0.830955749

00:09:41.648 --> 00:09:44.938 patients with double hit lymphoma

NOTE Confidence: 0.830955749

00:09:44.938 --> 00:09:48.163 who progressed after court had

NOTE Confidence: 0.830955749

00:09:48.163 --> 00:09:51.664 a very poor outcome with overall

NOTE Confidence: 0.830955749

00:09:51.664 --> 00:09:54.868 survival that was very short only

NOTE Confidence: 0.830955749

00:09:54.868 --> 00:09:57.430 in the order of 2.7 months.

NOTE Confidence: 0.830955749

00:09:57.430 --> 00:09:59.740 So this is a group of patients.

NOTE Confidence: 0.830955749

00:09:59.740 --> 00:10:00.718 That you know,

NOTE Confidence: 0.830955749

00:10:00.718 --> 00:10:02.348 if they progress after Carti,

NOTE Confidence: 0.830955749

00:10:02.350 --> 00:10:05.656 where they do need better salvage

NOTE Confidence: 0.830955749

00:10:05.656 --> 00:10:06.758 strategies for.

NOTE Confidence: 0.880673167142857

00:10:06.760 --> 00:10:10.155 So this was the largest analysis basically

NOTE Confidence: 0.880673167142857

00:10:10.155 --> 00:10:13.502 that provided some update as to what

NOTE Confidence: 0.880673167142857

00:10:13.502 --> 00:10:16.220 happens with these patients with double

NOTE Confidence: 0.880673167142857

00:10:16.301 --> 00:10:18.660 hit or dual overexpress or lymphomas.

NOTE Confidence: 0.880673167142857

00:10:18.660 --> 00:10:21.510 So those patients should be encouraged

NOTE Confidence: 0.880673167142857

00:10:21.510 --> 00:10:25.113 to participate in car T trials and and

NOTE Confidence: 0.880673167142857

00:10:25.113 --> 00:10:27.960 should be considered to receive it as
NOTE Confidence: 0.880673167142857

00:10:27.960 --> 00:10:30.418 as part of standard of care without
NOTE Confidence: 0.880673167142857

00:10:30.418 --> 00:10:33.344 fear that they're not going to respond
NOTE Confidence: 0.880673167142857

00:10:33.344 --> 00:10:36.427 as well as the as the regular DLBCL.
NOTE Confidence: 0.880673167142857

00:10:36.430 --> 00:10:39.545 So umm, what about patients who progress
NOTE Confidence: 0.880673167142857

00:10:39.545 --> 00:10:42.220 after CD19 directed cortisol therapy?
NOTE Confidence: 0.880673167142857

00:10:42.220 --> 00:10:44.820 This is a very challenging group of patients.
NOTE Confidence: 0.880673167142857

00:10:44.820 --> 00:10:47.277 As you know they die within typically
NOTE Confidence: 0.880673167142857

00:10:47.277 --> 00:10:49.760 die within three months of progressing
NOTE Confidence: 0.880673167142857

00:10:49.760 --> 00:10:50.670 after cartee.
NOTE Confidence: 0.880673167142857

00:10:50.670 --> 00:10:53.918 And so this was a study from Stanford
NOTE Confidence: 0.880673167142857

00:10:53.918 --> 00:10:56.969 that looked at City 22 directed car T.
NOTE Confidence: 0.880673167142857

00:10:56.970 --> 00:10:59.004 In patients who had previously received
NOTE Confidence: 0.880673167142857

00:10:59.004 --> 00:11:01.298 CD 19 directed car T cell therapy,
NOTE Confidence: 0.880673167142857

00:11:01.300 --> 00:11:03.170 this was initially published in
NOTE Confidence: 0.880673167142857

00:11:03.170 --> 00:11:05.040 Blood where they treated five.

NOTE Confidence: 0.880673167142857

00:11:05.040 --> 00:11:06.885 They treated three patients who

NOTE Confidence: 0.880673167142857

00:11:06.885 --> 00:11:09.645 had had all high risk features with

NOTE Confidence: 0.880673167142857

00:11:09.645 --> 00:11:11.735 five prior lines of therapy.

NOTE Confidence: 0.880673167142857

00:11:11.740 --> 00:11:12.660 Including Carte,

NOTE Confidence: 0.880673167142857

00:11:12.660 --> 00:11:16.340 in fact one of the patients had had

NOTE Confidence: 0.880673167142857

00:11:16.340 --> 00:11:18.285 commercial parties and targeting City

NOTE Confidence: 0.880673167142857

00:11:18.285 --> 00:11:21.184 19 and then also a by specific City

NOTE Confidence: 0.880673167142857

00:11:21.184 --> 00:11:24.108 19 and City 20 core T and had relapsed

NOTE Confidence: 0.880673167142857

00:11:24.108 --> 00:11:26.929 and all of those patients achieved a

NOTE Confidence: 0.880673167142857

00:11:26.929 --> 00:11:29.540 complete remission with the city 22

NOTE Confidence: 0.880673167142857

00:11:29.540 --> 00:11:32.920 targeted car T so that led to this.

NOTE Confidence: 0.875064976

00:11:35.240 --> 00:11:39.146 Moving forward to a larger study with

NOTE Confidence: 0.875064976

00:11:39.146 --> 00:11:42.847 38 participants rate up to 84 years

NOTE Confidence: 0.875064976

00:11:42.847 --> 00:11:45.733 old with a good performance status.

NOTE Confidence: 0.875064976

00:11:45.740 --> 00:11:47.180 They were heavily pretreated

NOTE Confidence: 0.875064976

00:11:47.180 --> 00:11:49.960 with three to 8 lines of therapy.
NOTE Confidence: 0.875064976

00:11:49.960 --> 00:11:51.984 The median was four.
NOTE Confidence: 0.875064976

00:11:51.984 --> 00:11:55.826 In fact, about 33rd of patients did not
NOTE Confidence: 0.875064976

00:11:55.826 --> 00:11:59.797 have remission to any prior line of therapy.
NOTE Confidence: 0.875064976

00:11:59.800 --> 00:12:02.362 About 20% had had a transplant
NOTE Confidence: 0.875064976

00:12:02.362 --> 00:12:04.530 and they had all had.
NOTE Confidence: 0.875064976

00:12:04.530 --> 00:12:08.275 Prior City 19 core T cell therapy.
NOTE Confidence: 0.875064976

00:12:08.280 --> 00:12:09.196 And umm.
NOTE Confidence: 0.875064976

00:12:09.196 --> 00:12:12.402 The median time from Luca Fresas to
NOTE Confidence: 0.875064976

00:12:12.402 --> 00:12:15.825 the Court 22 infusion was 18 days,
NOTE Confidence: 0.875064976

00:12:15.830 --> 00:12:20.168 so a bit shorter than what we would typically
NOTE Confidence: 0.875064976

00:12:20.170 --> 00:12:23.030 expect with the commercial products.
NOTE Confidence: 0.875064976

00:12:23.030 --> 00:12:26.270 And some patients did receive bridging.
NOTE Confidence: 0.875064976

00:12:26.270 --> 00:12:28.480 So the median follow-up has
NOTE Confidence: 0.875064976

00:12:28.480 --> 00:12:31.202 not reached the the two year
NOTE Confidence: 0.875064976

00:12:31.202 --> 00:12:33.728 mark for some of the cohorts.

NOTE Confidence: 0.875064976

00:12:33.730 --> 00:12:37.242 But very importantly the overall

NOTE Confidence: 0.875064976

00:12:37.242 --> 00:12:39.194 response rate and complete

NOTE Confidence: 0.875064976

00:12:39.194 --> 00:12:41.290 response rates were very high,

NOTE Confidence: 0.875064976

00:12:41.290 --> 00:12:45.686 higher than predicted 72% and CR of

NOTE Confidence: 0.875064976

00:12:45.690 --> 00:12:48.338 53% which is similar to what we see

NOTE Confidence: 0.875064976

00:12:48.338 --> 00:12:51.490 with first line card T and all of the

NOTE Confidence: 0.875064976

00:12:51.490 --> 00:12:53.110 complete responses have actually.

NOTE Confidence: 0.875064976

00:12:53.110 --> 00:12:54.014 Been very,

NOTE Confidence: 0.875064976

00:12:54.014 --> 00:12:56.726 very durable with only one patient

NOTE Confidence: 0.875064976

00:12:56.726 --> 00:12:59.507 who achieved the CR having relapsed.

NOTE Confidence: 0.875064976

00:12:59.510 --> 00:13:01.876 And and you can see there the

NOTE Confidence: 0.875064976

00:13:01.876 --> 00:13:03.311 progression free survival and

NOTE Confidence: 0.875064976

00:13:03.311 --> 00:13:05.447 overall survival curves on the left

NOTE Confidence: 0.875064976

00:13:05.447 --> 00:13:07.812 look look actually very good for a

NOTE Confidence: 0.875064976

00:13:07.812 --> 00:13:09.654 second line cartee and and compare

NOTE Confidence: 0.875064976

00:13:09.660 --> 00:13:12.960 very favourably to first line chart.
NOTE Confidence: 0.875064976

00:13:12.960 --> 00:13:17.099 And as you can see the majority of
NOTE Confidence: 0.875064976

00:13:17.099 --> 00:13:19.868 the patients experienced grade one
NOTE Confidence: 0.875064976

00:13:19.868 --> 00:13:25.070 or two cytokine release syndrome and.
NOTE Confidence: 0.875064976

00:13:25.070 --> 00:13:26.882 Neurologic toxicity associated
NOTE Confidence: 0.875064976

00:13:26.882 --> 00:13:29.902 with immune effector cell therapy
NOTE Confidence: 0.875064976

00:13:29.902 --> 00:13:34.520 or or eye canyons. And um.
NOTE Confidence: 0.875064976

00:13:34.520 --> 00:13:34.930 Interestingly,
NOTE Confidence: 0.875064976

00:13:34.930 --> 00:13:38.210 what they saw in the higher dose level,
NOTE Confidence: 0.875064976

00:13:38.210 --> 00:13:40.940 which was dose level 2 is that
NOTE Confidence: 0.875064976

00:13:40.940 --> 00:13:44.393 there was a significant number of
NOTE Confidence: 0.875064976

00:13:44.393 --> 00:13:47.890 patients that experienced what is
NOTE Confidence: 0.875064976

00:13:47.890 --> 00:13:51.820 a syndrome that's very much like.
NOTE Confidence: 0.875064976

00:13:51.820 --> 00:13:54.635 Of falsity claim for histiocytosis
NOTE Confidence: 0.875064976

00:13:54.635 --> 00:13:56.324 and it's it's.
NOTE Confidence: 0.875064976

00:13:56.330 --> 00:13:58.553 Got a name of its own of carnage LH

NOTE Confidence: 0.875064976

00:13:58.553 --> 00:14:00.859 where it's a syndrome of five ferritin,

NOTE Confidence: 0.875064976

00:14:00.860 --> 00:14:03.405 cytopenia square apathy and liver

NOTE Confidence: 0.875064976

00:14:03.405 --> 00:14:06.441 abnormalities and there was just in

NOTE Confidence: 0.875064976

00:14:06.441 --> 00:14:09.276 general more toxicity in those level 2.

NOTE Confidence: 0.875064976

00:14:09.280 --> 00:14:12.642 So dose level one had very was the one

NOTE Confidence: 0.875064976

00:14:12.642 --> 00:14:14.280 that had the results I showed you.

NOTE Confidence: 0.875064976

00:14:14.280 --> 00:14:17.142 So that's the dose that they're

NOTE Confidence: 0.875064976

00:14:17.142 --> 00:14:18.573 moving forward with.

NOTE Confidence: 0.875064976

00:14:18.580 --> 00:14:20.800 And then one patient developed

NOTE Confidence: 0.875064976

00:14:20.800 --> 00:14:23.609 treatment related MSDS and AML without

NOTE Confidence: 0.875064976

00:14:23.609 --> 00:14:26.669 evidence of lymphoma relapse which again.

NOTE Confidence: 0.875064976

00:14:26.670 --> 00:14:28.850 Underscores the importance of us

NOTE Confidence: 0.875064976

00:14:28.850 --> 00:14:31.030 following this patients long term.

NOTE Confidence: 0.81361711

00:14:33.680 --> 00:14:40.728 Um, so another study of interest is actually?

NOTE Confidence: 0.81361711

00:14:40.730 --> 00:14:45.326 Engineered allogeneic core T cell therapy,

NOTE Confidence: 0.81361711

00:14:45.330 --> 00:14:47.415 all the commercial products are
NOTE Confidence: 0.81361711

00:14:47.415 --> 00:14:49.500 autologous products and also the
NOTE Confidence: 0.81361711

00:14:49.572 --> 00:14:51.623 the one that I just presented the
NOTE Confidence: 0.81361711

00:14:51.623 --> 00:14:54.008 city 22 was an autologous product.
NOTE Confidence: 0.81361711

00:14:54.010 --> 00:14:58.013 This is a an aloe gamma delta cortisol
NOTE Confidence: 0.81361711

00:14:58.013 --> 00:15:00.834 therapy and actually it's a first in
NOTE Confidence: 0.81361711

00:15:00.834 --> 00:15:04.110 class it instead of targeting C19 like
NOTE Confidence: 0.81361711

00:15:04.110 --> 00:15:06.500 the commercial products it targets
NOTE Confidence: 0.81361711

00:15:06.576 --> 00:15:09.578 CD 20 and it has both adaptive and
NOTE Confidence: 0.81361711

00:15:09.578 --> 00:15:11.330 innate cytotoxic effector function.
NOTE Confidence: 0.81361711

00:15:11.330 --> 00:15:13.794 Which complement card targeting
NOTE Confidence: 0.81361711

00:15:13.794 --> 00:15:16.258 potentially enhancing is is
NOTE Confidence: 0.81361711

00:15:16.258 --> 00:15:19.469 efficacy and reducing antigen loss.
NOTE Confidence: 0.81361711

00:15:19.470 --> 00:15:21.422 It expresses MHC independent
NOTE Confidence: 0.81361711

00:15:21.422 --> 00:15:23.862 gamma delta T cell receptor.
NOTE Confidence: 0.81361711

00:15:23.870 --> 00:15:26.278 So the risk of GVHD is low without

NOTE Confidence: 0.81361711

00:15:26.278 --> 00:15:28.531 the need for gene editing which

NOTE Confidence: 0.81361711

00:15:28.531 --> 00:15:30.889 is more complex and takes longer.

NOTE Confidence: 0.81361711

00:15:30.890 --> 00:15:33.452 So this is the industry's most advanced

NOTE Confidence: 0.81361711

00:15:33.452 --> 00:15:36.236 core asset using Gamma Delta and they

NOTE Confidence: 0.81361711

00:15:36.236 --> 00:15:38.666 presented the multicenter phase one trial

NOTE Confidence: 0.81361711

00:15:38.735 --> 00:15:41.345 for relapsed refractory B cell lymphoma.

NOTE Confidence: 0.81361711

00:15:41.350 --> 00:15:43.235 Patients had to have CD20

NOTE Confidence: 0.81361711

00:15:43.235 --> 00:15:45.120 expression on their tumor cells.

NOTE Confidence: 0.81361711

00:15:45.120 --> 00:15:47.736 They had to have received at least two

NOTE Confidence: 0.81361711

00:15:47.736 --> 00:15:51.408 prior lines of therapy and at ash they

NOTE Confidence: 0.81361711

00:15:51.408 --> 00:15:53.710 presented the data for their first

NOTE Confidence: 0.81361711

00:15:53.710 --> 00:15:56.647 dose cohorts in a three by three dose

NOTE Confidence: 0.81361711

00:15:56.647 --> 00:15:59.272 escalation scheme and in dose Level 3.

NOTE Confidence: 0.81361711

00:15:59.280 --> 00:16:01.688 They did allow patients to be reduced

NOTE Confidence: 0.81361711

00:16:01.688 --> 00:16:04.379 a week later without any lymphodema,

NOTE Confidence: 0.81361711

00:16:04.380 --> 00:16:07.950 additional lymphodepletion chemotherapy.

NOTE Confidence: 0.81361711

00:16:07.950 --> 00:16:10.284 So the median number of therapies

NOTE Confidence: 0.81361711

00:16:10.284 --> 00:16:12.519 was four range two to five,

NOTE Confidence: 0.81361711

00:16:12.520 --> 00:16:15.268 they were heavily pretreated.

NOTE Confidence: 0.81361711

00:16:15.268 --> 00:16:20.072 And four of the nine patients who

NOTE Confidence: 0.81361711

00:16:20.072 --> 00:16:22.952 were evaluable had received prior

NOTE Confidence: 0.81361711

00:16:22.952 --> 00:16:25.976 anti CD19 car T cell therapy.

NOTE Confidence: 0.81361711

00:16:25.980 --> 00:16:27.620 It was very well tolerated.

NOTE Confidence: 0.81361711

00:16:27.620 --> 00:16:30.182 There was no reported graph versus

NOTE Confidence: 0.81361711

00:16:30.182 --> 00:16:32.946 host disease and there were no

NOTE Confidence: 0.81361711

00:16:32.946 --> 00:16:35.381 Grade 3 cytokine release syndrome

NOTE Confidence: 0.81361711

00:16:35.381 --> 00:16:36.842 or neurologic toxicity.

NOTE Confidence: 0.81361711

00:16:36.850 --> 00:16:39.846 And this is their preliminary efficacy data.

NOTE Confidence: 0.81361711

00:16:39.850 --> 00:16:43.634 So as you can see there's six months

NOTE Confidence: 0.81361711

00:16:43.634 --> 00:16:46.418 complete response rate was in the order

NOTE Confidence: 0.81361711

00:16:46.418 --> 00:16:50.546 of 67% and for patients in those Level 3,

NOTE Confidence: 0.81361711

00:16:50.550 --> 00:16:52.839 actually a small number of three patients,

NOTE Confidence: 0.81361711

00:16:52.840 --> 00:16:55.527 they had a complete response rate of 100%.

NOTE Confidence: 0.81361711

00:16:55.527 --> 00:16:58.749 So this compares very favorably to

NOTE Confidence: 0.81361711

00:16:58.749 --> 00:17:01.374 autologous products and the advantage

NOTE Confidence: 0.81361711

00:17:01.374 --> 00:17:05.070 being that it's an off the shelf product,

NOTE Confidence: 0.81361711

00:17:05.070 --> 00:17:07.554 so the turnaround time.

NOTE Confidence: 0.81361711

00:17:07.554 --> 00:17:09.417 It's extremely short.

NOTE Confidence: 0.81361711

00:17:09.420 --> 00:17:15.006 The cells perhaps are fitter than those

NOTE Confidence: 0.81361711

00:17:15.010 --> 00:17:18.100 obtained from a heavily pretreated patient,

NOTE Confidence: 0.81361711

00:17:18.100 --> 00:17:22.146 without much in the way of toxicity.

NOTE Confidence: 0.81361711

00:17:22.150 --> 00:17:24.098 And then more recently,

NOTE Confidence: 0.81361711

00:17:24.098 --> 00:17:27.910 the company opened a dose level 4 cohort,

NOTE Confidence: 0.81361711

00:17:27.910 --> 00:17:33.976 so now they have a larger number of patients.

NOTE Confidence: 0.81361711

00:17:33.980 --> 00:17:36.120 However,

NOTE Confidence: 0.81361711

00:17:36.120 --> 00:17:38.892 they do not have particularly the higher

NOTE Confidence: 0.81361711

00:17:38.892 --> 00:17:41.922 dose levels of three and four do not
NOTE Confidence: 0.81361711

00:17:41.922 --> 00:17:44.589 have have very short follow-up and the
NOTE Confidence: 0.81361711

00:17:44.589 --> 00:17:47.095 patients who have been treated so far,
NOTE Confidence: 0.81361711

00:17:47.100 --> 00:17:49.500 a good number of them if you see
NOTE Confidence: 0.81361711

00:17:49.500 --> 00:17:52.179 her in red have actually relapsed
NOTE Confidence: 0.81361711

00:17:52.180 --> 00:17:56.944 and so the durability of responses
NOTE Confidence: 0.81361711

00:17:56.944 --> 00:18:00.120 is still questionable and.
NOTE Confidence: 0.81361711

00:18:00.120 --> 00:18:01.206 You know,
NOTE Confidence: 0.81361711

00:18:01.206 --> 00:18:05.007 it has investors pretty much really worried.
NOTE Confidence: 0.81361711

00:18:05.010 --> 00:18:07.224 You know about how this product
NOTE Confidence: 0.81361711

00:18:07.224 --> 00:18:10.069 is going to do in the long run.
NOTE Confidence: 0.81361711

00:18:10.070 --> 00:18:12.177 But again we just need to to
NOTE Confidence: 0.81361711

00:18:12.177 --> 00:18:14.294 see what's gonna happen to these
NOTE Confidence: 0.81361711

00:18:14.294 --> 00:18:16.580 patients who are getting the higher
NOTE Confidence: 0.81361711

00:18:16.580 --> 00:18:18.508 doses with longer follow up.
NOTE Confidence: 0.81361711

00:18:18.510 --> 00:18:21.926 And you can see that the patients here

NOTE Confidence: 0.81361711

00:18:21.926 --> 00:18:24.349 highlighted in yellow are patients

NOTE Confidence: 0.81361711

00:18:24.349 --> 00:18:27.307 who all had prior cortisol therapy,

NOTE Confidence: 0.81361711

00:18:27.310 --> 00:18:29.690 anti CD19 cortisol therapy

NOTE Confidence: 0.81361711

00:18:29.690 --> 00:18:32.665 and they all have achieved

NOTE Confidence: 0.90459693375

00:18:32.670 --> 00:18:35.076 complete remission and.

NOTE Confidence: 0.90459693375

00:18:35.076 --> 00:18:39.086 Some of them are still.

NOTE Confidence: 0.90459693375

00:18:39.090 --> 00:18:42.120 Responding to treatment.

NOTE Confidence: 0.90459693375

00:18:42.120 --> 00:18:45.400 So I'm not going to spend a lot of time here,

NOTE Confidence: 0.90459693375

00:18:45.400 --> 00:18:48.193 but just to shift gears to bring

NOTE Confidence: 0.90459693375

00:18:48.193 --> 00:18:50.691 your attention that car T cell

NOTE Confidence: 0.90459693375

00:18:50.691 --> 00:18:52.726 therapy is also approved for

NOTE Confidence: 0.90459693375

00:18:52.726 --> 00:18:54.650 patients with follicular lymphoma.

NOTE Confidence: 0.90459693375

00:18:54.650 --> 00:18:57.980 In the third line setting and

NOTE Confidence: 0.90459693375

00:18:57.980 --> 00:19:00.826 this is based on two trials,

NOTE Confidence: 0.90459693375

00:19:00.826 --> 00:19:04.228 Zuma five with the access cell and

NOTE Confidence: 0.90459693375

00:19:04.228 --> 00:19:07.220 Elara with the TISAGENLECLEUCEL.
NOTE Confidence: 0.90459693375

00:19:07.220 --> 00:19:09.075 So this was the Zuma 5 update
NOTE Confidence: 0.90459693375

00:19:09.075 --> 00:19:10.919 with a 3 year survival.
NOTE Confidence: 0.90459693375

00:19:10.920 --> 00:19:13.614 You can see here that the
NOTE Confidence: 0.90459693375

00:19:13.614 --> 00:19:16.076 overall response rates and the
NOTE Confidence: 0.90459693375

00:19:16.076 --> 00:19:18.360 complete response rates with.
NOTE Confidence: 0.90459693375

00:19:18.360 --> 00:19:20.754 Car T cell therapy are very high
NOTE Confidence: 0.90459693375

00:19:20.754 --> 00:19:23.785 in the third line setting in both
NOTE Confidence: 0.90459693375

00:19:23.785 --> 00:19:26.185 patients with follicular lymphoma and
NOTE Confidence: 0.90459693375

00:19:26.185 --> 00:19:29.367 also in patients with marginal zone
NOTE Confidence: 0.90459693375

00:19:29.367 --> 00:19:31.992 lymphoma and progression free survival
NOTE Confidence: 0.90459693375

00:19:32.000 --> 00:19:34.946 is very good and overall survival
NOTE Confidence: 0.90459693375

00:19:34.946 --> 00:19:38.489 is very good for these patients.
NOTE Confidence: 0.90459693375

00:19:38.490 --> 00:19:41.250 With relatively long term follow-up,
NOTE Confidence: 0.90459693375

00:19:41.250 --> 00:19:43.626 because in the third line setting,
NOTE Confidence: 0.90459693375

00:19:43.630 --> 00:19:46.310 typically what we would expect

NOTE Confidence: 0.90459693375

00:19:46.310 --> 00:19:48.970 from a third line therapy is a

NOTE Confidence: 0.90459693375

00:19:48.970 --> 00:19:51.179 shorter duration of response that

NOTE Confidence: 0.90459693375

00:19:51.179 --> 00:19:53.402 is typically less than two years

NOTE Confidence: 0.90459693375

00:19:53.402 --> 00:19:55.250 and sometimes less than one year

NOTE Confidence: 0.90459693375

00:19:55.318 --> 00:19:57.098 depending on the product used.

NOTE Confidence: 0.90459693375

00:19:57.100 --> 00:19:59.404 But here you can see that the median

NOTE Confidence: 0.90459693375

00:19:59.404 --> 00:20:01.291 PFS for follicular lymphoma was

NOTE Confidence: 0.90459693375

00:20:01.291 --> 00:20:03.769 fourteen months and was not reached

NOTE Confidence: 0.90459693375

00:20:03.769 --> 00:20:05.890 for a marginal zone lymphoma.

NOTE Confidence: 0.764501193846154

00:20:08.460 --> 00:20:12.892 Umm. And then uh, similar data from the

NOTE Confidence: 0.764501193846154

00:20:12.892 --> 00:20:17.148 Elara study looking at Tisagenlecleucel,

NOTE Confidence: 0.764501193846154

00:20:17.150 --> 00:20:20.214 so also targeting CD19, but if with a

NOTE Confidence: 0.764501193846154

00:20:20.214 --> 00:20:22.673 different Co stimulatory molecule that

NOTE Confidence: 0.764501193846154

00:20:22.673 --> 00:20:29.104 is 41B with over two years of follow-up,

NOTE Confidence: 0.764501193846154

00:20:29.110 --> 00:20:31.480 patients who achieved complete response

NOTE Confidence: 0.764501193846154

00:20:31.480 --> 00:20:34.844 represented here in the top curve have
NOTE Confidence: 0.764501193846154

00:20:34.844 --> 00:20:37.144 not reached their median progression
NOTE Confidence: 0.764501193846154

00:20:37.144 --> 00:20:39.729 free survival and the anticipated.
NOTE Confidence: 0.764501193846154

00:20:39.730 --> 00:20:41.645 For all two year progression
NOTE Confidence: 0.764501193846154

00:20:41.645 --> 00:20:43.732 free survival is about 60%.
NOTE Confidence: 0.764501193846154

00:20:43.732 --> 00:20:45.388 Umm. So umm.
NOTE Confidence: 0.764501193846154

00:20:45.388 --> 00:20:48.148 There was also this additional
NOTE Confidence: 0.764501193846154

00:20:48.148 --> 00:20:50.347 presentation that compared access
NOTE Confidence: 0.764501193846154

00:20:50.347 --> 00:20:53.959 cell to other third line standard of
NOTE Confidence: 0.764501193846154

00:20:54.056 --> 00:20:57.226 care therapies for relapse refractory
NOTE Confidence: 0.764501193846154

00:20:57.226 --> 00:21:00.396 follicular lymphoma and this was
NOTE Confidence: 0.764501193846154

00:21:00.400 --> 00:21:04.550 retrospective in nature but compared
NOTE Confidence: 0.764501193846154

00:21:04.550 --> 00:21:08.270 to scholar five study that does
NOTE Confidence: 0.764501193846154

00:21:08.270 --> 00:21:11.160 show a substantial improvement with
NOTE Confidence: 0.764501193846154

00:21:11.254 --> 00:21:14.560 axicom taken with with the cellular
NOTE Confidence: 0.764501193846154

00:21:14.560 --> 00:21:17.850 therapy compared to other third line.

NOTE Confidence: 0.764501193846154
00:21:17.850 --> 00:21:20.360 Therapies.
NOTE Confidence: 0.764501193846154
00:21:20.360 --> 00:21:21.436 But again,
NOTE Confidence: 0.764501193846154
00:21:21.436 --> 00:21:24.664 it's not a randomized study and
NOTE Confidence: 0.764501193846154
00:21:24.664 --> 00:21:26.120 it's different to.
NOTE Confidence: 0.764501193846154
00:21:26.120 --> 00:21:28.395 There may be differences in
NOTE Confidence: 0.764501193846154
00:21:28.395 --> 00:21:30.215 baseline characteristics that do
NOTE Confidence: 0.764501193846154
00:21:30.215 --> 00:21:32.318 restrict cross study comparisons,
NOTE Confidence: 0.764501193846154
00:21:32.320 --> 00:21:34.816 but this is what the progression
NOTE Confidence: 0.764501193846154
00:21:34.816 --> 00:21:37.314 free overall survival and time to
NOTE Confidence: 0.764501193846154
00:21:37.314 --> 00:21:39.974 next treatment look like in blue for
NOTE Confidence: 0.764501193846154
00:21:39.974 --> 00:21:41.921 patients who had cortisol therapy
NOTE Confidence: 0.764501193846154
00:21:41.921 --> 00:21:44.615 versus at the bottom in red for
NOTE Confidence: 0.764501193846154
00:21:44.615 --> 00:21:47.800 patients who have who would have had
NOTE Confidence: 0.764501193846154
00:21:47.800 --> 00:21:51.610 other third line standard of care therapies.
NOTE Confidence: 0.764501193846154
00:21:51.610 --> 00:21:54.666 And this was published recently in in blood.
NOTE Confidence: 0.764501193846154

00:21:54.670 --> 00:21:58.222 And then I I want to also bring
NOTE Confidence: 0.764501193846154

00:21:58.222 --> 00:22:00.501 attention to the study published
NOTE Confidence: 0.764501193846154

00:22:00.501 --> 00:22:03.469 by by our very own group led by
NOTE Confidence: 0.764501193846154

00:22:03.469 --> 00:22:06.104 Kunal under the mentorship of
NOTE Confidence: 0.764501193846154

00:22:06.104 --> 00:22:08.829 Scott Huntington where the cost
NOTE Confidence: 0.764501193846154

00:22:08.829 --> 00:22:11.392 effectiveness of car T cell therapy
NOTE Confidence: 0.764501193846154

00:22:11.392 --> 00:22:14.512 was compared in adults with relapsed
NOTE Confidence: 0.764501193846154

00:22:14.512 --> 00:22:19.240 refractory follicular lymphoma and.
NOTE Confidence: 0.764501193846154

00:22:19.240 --> 00:22:22.236 The cost of core T cell therapy
NOTE Confidence: 0.764501193846154

00:22:22.236 --> 00:22:26.160 is about \$730,000 as opposed to
NOTE Confidence: 0.764501193846154

00:22:26.160 --> 00:22:28.764 \$450,000 for the standard of care
NOTE Confidence: 0.764501193846154

00:22:28.764 --> 00:22:31.656 with an eyesore of about 80,000
NOTE Confidence: 0.764501193846154

00:22:31.656 --> 00:22:34.336 for quality adjusted life years.
NOTE Confidence: 0.764501193846154

00:22:34.340 --> 00:22:36.730 But I think considering the.
NOTE Confidence: 0.8257596575

00:22:38.780 --> 00:22:41.138 Risks associated with car T cell
NOTE Confidence: 0.8257596575

00:22:41.138 --> 00:22:44.048 therapy in terms of cytokine release

NOTE Confidence: 0.8257596575

00:22:44.048 --> 00:22:46.568 syndrome and neurologic toxicity.

NOTE Confidence: 0.839117332222222

00:22:48.700 --> 00:22:52.795 We need to do a better job and have

NOTE Confidence: 0.839117332222222

00:22:52.800 --> 00:22:55.182 a longer follow-up and and randomized

NOTE Confidence: 0.839117332222222

00:22:55.182 --> 00:22:57.519 comparisons to other lines of therapy.

NOTE Confidence: 0.839117332222222

00:22:57.520 --> 00:23:00.604 So that we subject these patients

NOTE Confidence: 0.839117332222222

00:23:00.604 --> 00:23:03.934 to who have the majority of them

NOTE Confidence: 0.839117332222222

00:23:03.934 --> 00:23:06.312 have long progression free survival

NOTE Confidence: 0.839117332222222

00:23:06.312 --> 00:23:09.189 so that we subject them to minimal

NOTE Confidence: 0.839117332222222

00:23:09.189 --> 00:23:12.360 as as minimal toxicity as we can.

NOTE Confidence: 0.839117332222222

00:23:12.360 --> 00:23:15.104 And particularly now we have a new

NOTE Confidence: 0.839117332222222

00:23:15.104 --> 00:23:16.730 bispecific antibody approved for

NOTE Confidence: 0.839117332222222

00:23:16.730 --> 00:23:18.650 follicular lymphoma which is not.

NOTE Confidence: 0.839117332222222

00:23:18.650 --> 00:23:21.538 A part of these?

NOTE Confidence: 0.839117332222222

00:23:21.540 --> 00:23:24.868 Cost effectiveness comparison here,

NOTE Confidence: 0.839117332222222

00:23:24.868 --> 00:23:27.919 but I think that's also going to play

NOTE Confidence: 0.839117332222222

00:23:27.919 --> 00:23:30.966 a role and we need to see how in the
NOTE Confidence: 0.839117332222222

00:23:30.966 --> 00:23:33.642 long run we're going to best sequence
NOTE Confidence: 0.839117332222222

00:23:33.642 --> 00:23:35.807 these these therapies based on.
NOTE Confidence: 0.877115921428571

00:23:38.250 --> 00:23:40.140 The the way of administration
NOTE Confidence: 0.877115921428571

00:23:40.140 --> 00:23:42.030 you know multiple times versus
NOTE Confidence: 0.877115921428571

00:23:42.102 --> 00:23:43.870 one time patient preference,
NOTE Confidence: 0.877115921428571

00:23:43.870 --> 00:23:47.262 toxicities and cost effectiveness.
NOTE Confidence: 0.877115921428571

00:23:47.262 --> 00:23:50.360 So um. I'm going to switch gears
NOTE Confidence: 0.877115921428571

00:23:50.360 --> 00:23:51.760 now to mantle cell lymphoma.
NOTE Confidence: 0.877115921428571

00:23:51.760 --> 00:23:55.440 This is abstract 623 which is phase
NOTE Confidence: 0.877115921428571

00:23:55.440 --> 00:23:58.747 one to two two study of a tandem
NOTE Confidence: 0.877115921428571

00:23:58.747 --> 00:24:01.901 by specific anti CD20, anti CD 19.
NOTE Confidence: 0.877115921428571

00:24:01.901 --> 00:24:04.463 We do have a product that's
NOTE Confidence: 0.877115921428571

00:24:04.463 --> 00:24:07.065 Brexit prapta gene that's already
NOTE Confidence: 0.877115921428571

00:24:07.065 --> 00:24:10.650 approved but it is very toxic and.
NOTE Confidence: 0.83040595

00:24:13.070 --> 00:24:16.566 There are. There's the hypothesis

NOTE Confidence: 0.83040595

00:24:16.566 --> 00:24:20.178 of this study was that if we use a

NOTE Confidence: 0.83040595

00:24:20.178 --> 00:24:22.046 bispecific tandem targeting product

NOTE Confidence: 0.83040595

00:24:22.046 --> 00:24:26.930 targeting both City 20 and city 19 with.

NOTE Confidence: 0.83040595

00:24:26.930 --> 00:24:29.036 Expansion with the I7 and I-15

NOTE Confidence: 0.83040595

00:24:29.036 --> 00:24:31.482 that we might get less exhausted

NOTE Confidence: 0.83040595

00:24:31.482 --> 00:24:33.887 car products with more durable,

NOTE Confidence: 0.83040595

00:24:33.890 --> 00:24:36.570 even more durable clinical activity.

NOTE Confidence: 0.83040595

00:24:36.570 --> 00:24:42.538 And this product actually is manufactured

NOTE Confidence: 0.83040595

00:24:42.538 --> 00:24:44.886 using climax prodigy device.

NOTE Confidence: 0.83040595

00:24:44.890 --> 00:24:47.098 It's a fresh infusion and the

NOTE Confidence: 0.83040595

00:24:47.098 --> 00:24:49.030 manufacturing time is quite short,

NOTE Confidence: 0.83040595

00:24:49.030 --> 00:24:51.606 is somewhere between 8:00 and 12 days.

NOTE Confidence: 0.83040595

00:24:51.610 --> 00:24:54.760 So for patients with rapidly

NOTE Confidence: 0.83040595

00:24:54.760 --> 00:24:57.280 progressive mantle cell lymphoma.

NOTE Confidence: 0.83040595

00:24:57.280 --> 00:25:00.232 It's a great product to have that we

NOTE Confidence: 0.83040595

00:25:00.232 --> 00:25:03.269 can infuse rapidly and you can see here
NOTE Confidence: 0.83040595

00:25:03.269 --> 00:25:06.226 that the manufacturing rate was very high,
NOTE Confidence: 0.83040595

00:25:06.230 --> 00:25:09.200 100% with its closed system.
NOTE Confidence: 0.83040595

00:25:09.200 --> 00:25:12.455 There were no Grade 3 cytokine release
NOTE Confidence: 0.83040595

00:25:12.460 --> 00:25:14.882 syndrome cases and there was only one
NOTE Confidence: 0.83040595

00:25:14.882 --> 00:25:16.918 patient with grade three eye cans.
NOTE Confidence: 0.83040595

00:25:16.920 --> 00:25:18.540 They were patients that had
NOTE Confidence: 0.83040595

00:25:18.540 --> 00:25:20.780 at least 4 lines of therapy.
NOTE Confidence: 0.83040595

00:25:20.780 --> 00:25:22.640 They were all exposed to BTK
NOTE Confidence: 0.83040595

00:25:22.640 --> 00:25:24.989 inhibitors and you can look at a
NOTE Confidence: 0.83040595

00:25:24.989 --> 00:25:26.734 long term progression free survival.
NOTE Confidence: 0.83040595

00:25:26.740 --> 00:25:29.365 Looks excellent and and the we already
NOTE Confidence: 0.83040595

00:25:29.365 --> 00:25:31.975 have the diffuse large B cell lymphoma
NOTE Confidence: 0.83040595

00:25:31.975 --> 00:25:34.886 study but we're gonna go ahead and open
NOTE Confidence: 0.83040595

00:25:34.886 --> 00:25:37.378 this for mantle cell lymphoma at Yale.
NOTE Confidence: 0.83040595

00:25:37.380 --> 00:25:38.490 And then finally,

NOTE Confidence: 0.83040595

00:25:38.490 --> 00:25:41.742 I'm going to switch gears to talk a little

NOTE Confidence: 0.83040595

00:25:41.742 --> 00:25:44.382 bit about T cell and B cell leukemia.

NOTE Confidence: 0.83040595

00:25:44.382 --> 00:25:49.198 So this was published in blood this year.

NOTE Confidence: 0.83040595

00:25:49.200 --> 00:25:51.042 As we know,

NOTE Confidence: 0.83040595

00:25:51.042 --> 00:25:55.066 finding a target for T cell lymphomas

NOTE Confidence: 0.83040595

00:25:55.066 --> 00:25:57.676 and leukemias has been challenging.

NOTE Confidence: 0.83040595

00:25:57.680 --> 00:26:00.976 City 7 is a very commonly expressed antigen,

NOTE Confidence: 0.83040595

00:26:00.980 --> 00:26:04.553 but it is expressed in the T cells and

NOTE Confidence: 0.83040595

00:26:04.553 --> 00:26:07.912 there is concern that there's going to be.

NOTE Confidence: 0.83040595

00:26:07.912 --> 00:26:10.757 Fratricide the way this is a Chinese

NOTE Confidence: 0.83040595

00:26:10.757 --> 00:26:13.227 group that they actually developed

NOTE Confidence: 0.83040595

00:26:13.227 --> 00:26:16.767 a novel methyl method of CD7 antigen

NOTE Confidence: 0.83040595

00:26:16.767 --> 00:26:19.731 masking that makes the cells fratricide

NOTE Confidence: 0.83040595

00:26:19.731 --> 00:26:23.865 resistant and this was their initial

NOTE Confidence: 0.83040595

00:26:23.865 --> 00:26:27.616 study was published earlier of these

NOTE Confidence: 0.83040595

00:26:27.616 --> 00:26:30.748 naturally selected core T cells without
NOTE Confidence: 0.83040595

00:26:30.748 --> 00:26:34.040 genetic modification and then abstract
NOTE Confidence: 0.83040595

00:26:34.040 --> 00:26:37.410 980 looked at 53 patients that had.
NOTE Confidence: 0.83040595

00:26:37.410 --> 00:26:40.945 Relapse refractory T cell all or T cell
NOTE Confidence: 0.83040595

00:26:40.945 --> 00:26:42.881 lymphoblastic lymphoma treated with
NOTE Confidence: 0.83040595

00:26:42.881 --> 00:26:46.792 this therapy you can see they were very
NOTE Confidence: 0.83040595

00:26:46.792 --> 00:26:49.276 heavily pretreated group of patients
NOTE Confidence: 0.83040595

00:26:49.276 --> 00:26:53.394 about half of them had more than 5%
NOTE Confidence: 0.83040595

00:26:53.394 --> 00:26:57.132 and blast and their mayoral some of
NOTE Confidence: 0.83040595

00:26:57.132 --> 00:27:01.950 them had extramedullary disease even and.
NOTE Confidence: 0.83040595

00:27:01.950 --> 00:27:03.830 They had.
NOTE Confidence: 0.83040595

00:27:03.830 --> 00:27:06.994 Very decent overall end event free survival
NOTE Confidence: 0.83040595

00:27:06.994 --> 00:27:09.889 in this relapse refractory setting.
NOTE Confidence: 0.83040595

00:27:09.890 --> 00:27:13.446 So the median follow-up is pretty long,
NOTE Confidence: 0.83040595

00:27:13.450 --> 00:27:14.246 206 days.
NOTE Confidence: 0.83040595

00:27:14.246 --> 00:27:16.634 Some of the data is here.

NOTE Confidence: 0.83040595

00:27:16.640 --> 00:27:19.664 I'm not going to go into it in detail,

NOTE Confidence: 0.83040595

00:27:19.670 --> 00:27:24.966 but suffice it to say that the

NOTE Confidence: 0.83040595

00:27:24.966 --> 00:27:29.096 18 month overall survival 75% and

NOTE Confidence: 0.83040595

00:27:29.096 --> 00:27:31.998 event free survival of 53% and.

NOTE Confidence: 0.83040595

00:27:31.998 --> 00:27:35.502 Some patients were bridged to an

NOTE Confidence: 0.83040595

00:27:35.502 --> 00:27:38.419 allogeneic stem cell transplant,

NOTE Confidence: 0.83040595

00:27:38.420 --> 00:27:41.516 but many patients were not and

NOTE Confidence: 0.83040595

00:27:41.516 --> 00:27:45.236 and the ones that achieved CR were

NOTE Confidence: 0.83040595

00:27:45.236 --> 00:27:47.996 able to maintain the CR.

NOTE Confidence: 0.83040595

00:27:48.000 --> 00:27:52.266 So umm, this was highly effective.

NOTE Confidence: 0.83040595

00:27:52.270 --> 00:27:54.730 They including in patients with

NOTE Confidence: 0.83040595

00:27:54.730 --> 00:27:56.698 extramedullary involvement or patients

NOTE Confidence: 0.83040595

00:27:56.698 --> 00:28:00.350 with have prior cart and they did

NOTE Confidence: 0.83040595

00:28:00.350 --> 00:28:04.410 identify a patients with the SIL

NOTE Confidence: 0.83040595

00:28:04.410 --> 00:28:07.770 tile one having a Porter response

NOTE Confidence: 0.83040595

00:28:07.770 --> 00:28:11.149 and early relapses and when relapses
NOTE Confidence: 0.83040595

00:28:11.149 --> 00:28:14.329 occur occurred they did see loss
NOTE Confidence: 0.83040595

00:28:14.329 --> 00:28:16.770 of city 7 expression.
NOTE Confidence: 0.83040595

00:28:16.770 --> 00:28:20.094 Now the Stephan Grupp group at
NOTE Confidence: 0.83040595

00:28:20.094 --> 00:28:22.310 Penn presented this abstract
NOTE Confidence: 0.762712658

00:28:22.405 --> 00:28:26.017 of City 22 targeted cartes in children
NOTE Confidence: 0.762712658

00:28:26.017 --> 00:28:29.358 and young adults after having relapsed
NOTE Confidence: 0.762712658

00:28:29.358 --> 00:28:34.834 post city 19 car T cell therapy for ALS
NOTE Confidence: 0.762712658

00:28:34.834 --> 00:28:38.902 and they enrolled 19 patients that had
NOTE Confidence: 0.762712658

00:28:38.902 --> 00:28:41.086 a product successfully manufactured.
NOTE Confidence: 0.762712658

00:28:41.090 --> 00:28:42.782 17 patients were infused.
NOTE Confidence: 0.762712658

00:28:42.782 --> 00:28:45.320 All of them had sitting negative
NOTE Confidence: 0.762712658

00:28:45.400 --> 00:28:47.300 disease that had relapsed.
NOTE Confidence: 0.762712658

00:28:47.300 --> 00:28:50.724 Postcard T and some of them had received
NOTE Confidence: 0.762712658

00:28:50.724 --> 00:28:53.057 blinatumomab and inotuzumab and nine
NOTE Confidence: 0.762712658

00:28:53.057 --> 00:28:55.853 had had a prior transplant including

NOTE Confidence: 0.762712658

00:28:55.853 --> 00:28:58.799 three with multiple prior transplants.

NOTE Confidence: 0.762712658

00:28:58.800 --> 00:29:02.076 They the bone marrow blasts pre infusion

NOTE Confidence: 0.762712658

00:29:02.076 --> 00:29:05.624 were high and you can see here that the

NOTE Confidence: 0.762712658

00:29:05.624 --> 00:29:07.985 probability of survival for this group

NOTE Confidence: 0.762712658

00:29:07.985 --> 00:29:12.140 of patients getting city 22 therapy.

NOTE Confidence: 0.762712658

00:29:12.140 --> 00:29:18.160 Is is pretty good the 18 month?

NOTE Confidence: 0.762712658

00:29:18.160 --> 00:29:20.831 Uh, overall survival,

NOTE Confidence: 0.762712658

00:29:20.831 --> 00:29:23.837 actually they have been even longer

NOTE Confidence: 0.762712658

00:29:23.837 --> 00:29:28.060 follow-up for this study, but.

NOTE Confidence: 0.762712658

00:29:28.060 --> 00:29:31.420 You can see here that the

NOTE Confidence: 0.762712658

00:29:31.420 --> 00:29:33.100 probability of survival.

NOTE Confidence: 0.762712658

00:29:33.100 --> 00:29:38.530 At 18 month at 18 month Mark is still

NOTE Confidence: 0.762712658

00:29:38.530 --> 00:29:42.055 relatively decent for patients who

NOTE Confidence: 0.762712658

00:29:42.055 --> 00:29:44.860 otherwise most of them as you all

NOTE Confidence: 0.762712658

00:29:44.860 --> 00:29:47.315 know would have very poor outcomes

NOTE Confidence: 0.762712658

00:29:47.315 --> 00:29:50.237 and would succumb to their disease.
NOTE Confidence: 0.762712658

00:29:50.240 --> 00:29:55.168 So now they have almost 30 months of
NOTE Confidence: 0.762712658

00:29:55.168 --> 00:29:58.332 follow-up and the median relapse free
NOTE Confidence: 0.762712658

00:29:58.332 --> 00:30:01.230 survival is about five months and
NOTE Confidence: 0.762712658

00:30:01.324 --> 00:30:04.378 overall survival is about 16 months.
NOTE Confidence: 0.762712658

00:30:04.380 --> 00:30:07.579 So there were two patients that also
NOTE Confidence: 0.762712658

00:30:07.579 --> 00:30:10.931 worried treated with this for city 22
NOTE Confidence: 0.762712658

00:30:10.931 --> 00:30:13.296 relapse disease after initial infusion
NOTE Confidence: 0.762712658

00:30:13.296 --> 00:30:16.910 and one of them went into remission again.
NOTE Confidence: 0.762712658

00:30:16.910 --> 00:30:20.206 So there is a possibility of of retreating
NOTE Confidence: 0.762712658

00:30:20.206 --> 00:30:24.190 these patients and all of that data is here.
NOTE Confidence: 0.762712658

00:30:24.190 --> 00:30:27.690 But I just want to emphasize that we can
NOTE Confidence: 0.762712658

00:30:27.690 --> 00:30:30.986 salvage a portion of patients who fail CD 19.
NOTE Confidence: 0.762712658

00:30:30.990 --> 00:30:34.230 You can see here 77% achieva.
NOTE Confidence: 0.762712658

00:30:34.230 --> 00:30:38.850 CR and including undetectable MRD by flow.
NOTE Confidence: 0.762712658

00:30:38.850 --> 00:30:40.540 Um.

NOTE Confidence: 0.762712658

00:30:40.540 --> 00:30:42.691 So you know,

NOTE Confidence: 0.762712658

00:30:42.691 --> 00:30:46.993 they do develop toxicity and particularly.

NOTE Confidence: 0.762712658

00:30:47.000 --> 00:30:50.164 The risk of infections in is extremely

NOTE Confidence: 0.762712658

00:30:50.164 --> 00:30:52.400 high and cytopenias after back-to-back

NOTE Confidence: 0.762712658

00:30:52.400 --> 00:30:54.450 Carter cell therapies like this.

NOTE Confidence: 0.762712658

00:30:54.450 --> 00:30:57.765 So they had successful manufacturing

NOTE Confidence: 0.762712658

00:30:57.765 --> 00:31:01.718 again with an autologous product and

NOTE Confidence: 0.762712658

00:31:01.718 --> 00:31:04.946 there were high initial response rates

NOTE Confidence: 0.762712658

00:31:04.946 --> 00:31:08.293 but there are later recurrences and

NOTE Confidence: 0.762712658

00:31:08.293 --> 00:31:11.670 I think what was being looked at now

NOTE Confidence: 0.762712658

00:31:11.670 --> 00:31:14.731 is how to combine City 19 and City 22

NOTE Confidence: 0.762712658

00:31:14.731 --> 00:31:17.280 to to decrease the risk of relapse.

NOTE Confidence: 0.762712658

00:31:17.280 --> 00:31:18.042 I'm not gonna.

NOTE Confidence: 0.762712658

00:31:18.042 --> 00:31:19.820 I know we're running out of time,

NOTE Confidence: 0.762712658

00:31:19.820 --> 00:31:22.396 so I'm not going to spend too

NOTE Confidence: 0.762712658

00:31:22.396 --> 00:31:25.688 much time on on this abstract,
NOTE Confidence: 0.762712658

00:31:25.688 --> 00:31:28.236 but it did compare.
NOTE Confidence: 0.762712658

00:31:28.240 --> 00:31:30.760 Car T cell therapy in both patients
NOTE Confidence: 0.762712658

00:31:30.760 --> 00:31:33.227 who had received a blinatumomab and
NOTE Confidence: 0.762712658

00:31:33.227 --> 00:31:35.849 inotuzumab and patients who had not
NOTE Confidence: 0.762712658

00:31:35.849 --> 00:31:38.641 received blina or inotuzumab and this is
NOTE Confidence: 0.762712658

00:31:38.641 --> 00:31:41.718 in the adult population where they did
NOTE Confidence: 0.762712658

00:31:41.718 --> 00:31:44.298 this propensity score matching analysis.
NOTE Confidence: 0.762712658

00:31:44.300 --> 00:31:46.718 And what they actually find found
NOTE Confidence: 0.762712658

00:31:46.718 --> 00:31:49.673 is that the group that received car
NOTE Confidence: 0.762712658

00:31:49.673 --> 00:31:52.606 T cell therapy with access cell had
NOTE Confidence: 0.762712658

00:31:52.690 --> 00:31:55.460 much higher complete response rates
NOTE Confidence: 0.762712658

00:31:55.460 --> 00:31:58.856 of 85% versus patients who had.
NOTE Confidence: 0.762712658

00:31:58.860 --> 00:32:02.184 Other standard of care approaches also
NOTE Confidence: 0.762712658

00:32:02.184 --> 00:32:04.690 predominantly chemotherapy of 35% with
NOTE Confidence: 0.762712658

00:32:04.690 --> 00:32:07.210 a median overall survival that was

NOTE Confidence: 0.762712658

00:32:07.210 --> 00:32:10.906 higher at 16 months versus about five months.

NOTE Confidence: 0.762712658

00:32:10.910 --> 00:32:14.006 And this was true in both patients who

NOTE Confidence: 0.762712658

00:32:14.006 --> 00:32:16.846 were treated with blue 99-O2 zimat before,

NOTE Confidence: 0.762712658

00:32:16.846 --> 00:32:19.395 but also patients who were treatment

NOTE Confidence: 0.762712658

00:32:19.395 --> 00:32:22.090 naive that they both of those groups.

NOTE Confidence: 0.762712658

00:32:22.090 --> 00:32:25.114 For both of those groups we should consider

NOTE Confidence: 0.762712658

00:32:25.114 --> 00:32:28.119 car T because patients do respond.

NOTE Confidence: 0.844443311538462

00:32:28.120 --> 00:32:31.249 And and may have improved outcomes compared

NOTE Confidence: 0.844443311538462

00:32:31.249 --> 00:32:34.059 to other standard of care approaches.

NOTE Confidence: 0.844443311538462

00:32:34.060 --> 00:32:36.685 The the relapse phenotype is very important

NOTE Confidence: 0.844443311538462

00:32:36.685 --> 00:32:39.558 and it informs our therapeutic decisions.

NOTE Confidence: 0.844443311538462

00:32:39.560 --> 00:32:43.004 So about 22% of patients will relapse

NOTE Confidence: 0.844443311538462

00:32:43.004 --> 00:32:46.259 with City 19 positive disease,

NOTE Confidence: 0.844443311538462

00:32:46.260 --> 00:32:49.522 about 15% with city 19 negative AL

NOTE Confidence: 0.844443311538462

00:32:49.522 --> 00:32:51.883 and about 3% have lineage switched.

NOTE Confidence: 0.844443311538462

00:32:51.883 --> 00:32:54.130 And the group that has lineage switch
NOTE Confidence: 0.844443311538462

00:32:54.191 --> 00:32:56.543 actually is the group that has the poorest
NOTE Confidence: 0.844443311538462

00:32:56.543 --> 00:32:58.318 outcomes and they have quite poor.
NOTE Confidence: 0.844443311538462

00:32:58.320 --> 00:33:02.058 Outcomes, even with cartee cell therapy.
NOTE Confidence: 0.844443311538462

00:33:02.060 --> 00:33:05.572 And then post Cartee there is even more
NOTE Confidence: 0.844443311538462

00:33:05.572 --> 00:33:07.819 increasing complexity of the relapse
NOTE Confidence: 0.844443311538462

00:33:07.819 --> 00:33:10.411 immunophenotype and the most difficult of
NOTE Confidence: 0.844443311538462

00:33:10.411 --> 00:33:13.675 all group to to deal with is the group
NOTE Confidence: 0.844443311538462

00:33:13.675 --> 00:33:16.790 that postcard team now have both city
NOTE Confidence: 0.844443311538462

00:33:16.790 --> 00:33:20.484 19 and CD20 negative AL and again the
NOTE Confidence: 0.844443311538462

00:33:20.484 --> 00:33:25.390 patients with this lineage switch, So what?
NOTE Confidence: 0.844443311538462

00:33:25.390 --> 00:33:29.287 This is uh the the the group from the
NOTE Confidence: 0.844443311538462

00:33:29.287 --> 00:33:32.797 NCI new Rally that published recently
NOTE Confidence: 0.844443311538462

00:33:32.797 --> 00:33:35.786 and also presented at ASH that patients
NOTE Confidence: 0.844443311538462

00:33:35.786 --> 00:33:38.276 who get blinatumomab prior to car
NOTE Confidence: 0.844443311538462

00:33:38.276 --> 00:33:41.782 T cell therapy and do not achieve a

NOTE Confidence: 0.844443311538462
00:33:41.782 --> 00:33:44.503 complete response to blinatumomab have
NOTE Confidence: 0.844443311538462
00:33:44.503 --> 00:33:47.701 the have very poor outcomes postcard
NOTE Confidence: 0.844443311538462
00:33:47.701 --> 00:33:52.194 T and and that again having city 19
NOTE Confidence: 0.844443311538462
00:33:52.194 --> 00:33:55.342 damn disease pre Carty will influence.
NOTE Confidence: 0.844443311538462
00:33:55.342 --> 00:33:58.078 The postcard T cell relapse phenotype
NOTE Confidence: 0.844443311538462
00:33:58.078 --> 00:34:01.193 that a lot of those patients will
NOTE Confidence: 0.844443311538462
00:34:01.193 --> 00:34:03.630 have city 19 negative disease at,
NOTE Confidence: 0.844443311538462
00:34:03.630 --> 00:34:05.639 at the time of relapse and they
NOTE Confidence: 0.844443311538462
00:34:05.639 --> 00:34:07.749 will also have very poor outcomes.
NOTE Confidence: 0.844443311538462
00:34:07.750 --> 00:34:10.423 So it's very important in a L for us
NOTE Confidence: 0.844443311538462
00:34:10.423 --> 00:34:13.347 now to really break down the groups
NOTE Confidence: 0.844443311538462
00:34:13.347 --> 00:34:15.911 and follow these patients not just
NOTE Confidence: 0.844443311538462
00:34:15.911 --> 00:34:18.275 with B cell aplasia but actually
NOTE Confidence: 0.844443311538462
00:34:18.275 --> 00:34:22.202 follow them even more closely with
NOTE Confidence: 0.844443311538462
00:34:22.202 --> 00:34:26.117 MRD by NGS techniques because.
NOTE Confidence: 0.844443311538462

00:34:26.120 --> 00:34:28.800 Some patients.
NOTE Confidence: 0.844443311538462

00:34:28.800 --> 00:34:31.176 May still have some persistent B cells there,
NOTE Confidence: 0.844443311538462

00:34:31.180 --> 00:34:33.210 but still relapse early and we really
NOTE Confidence: 0.844443311538462

00:34:33.210 --> 00:34:35.176 need to move those patients toward
NOTE Confidence: 0.844443311538462

00:34:35.176 --> 00:34:37.577 clinical trials or or doing an urgent
NOTE Confidence: 0.844443311538462

00:34:37.638 --> 00:34:39.498 allogeneic stem cell transplant.
NOTE Confidence: 0.844443311538462

00:34:39.500 --> 00:34:41.866 So I think that perhaps we'll leave
NOTE Confidence: 0.844443311538462

00:34:41.866 --> 00:34:43.971 questions at the end to allow
NOTE Confidence: 0.844443311538462

00:34:43.971 --> 00:34:45.676 also doctor Gowda to present.
NOTE Confidence: 0.844443311538462

00:34:45.680 --> 00:34:47.588 So I'm going to stop sharing.
NOTE Confidence: 0.8595013

00:34:50.700 --> 00:34:54.860 All right. That was an awful
NOTE Confidence: 0.8595013

00:34:54.860 --> 00:34:57.200 lot of exciting information.
NOTE Confidence: 0.8595013

00:34:57.200 --> 00:34:58.532 There is one question
NOTE Confidence: 0.8595013

00:34:58.532 --> 00:35:00.298 in the Q&A doctor Soufi,
NOTE Confidence: 0.8595013

00:35:00.298 --> 00:35:02.860 maybe you can take a look while
NOTE Confidence: 0.8595013

00:35:02.940 --> 00:35:04.960 Doctor Gowda is presenting.

NOTE Confidence: 0.8595013

00:35:04.960 --> 00:35:08.056 So next is Doctor Lohith Gowda.

NOTE Confidence: 0.8595013

00:35:08.060 --> 00:35:09.506 He's assistant professor

NOTE Confidence: 0.8595013

00:35:09.506 --> 00:35:11.434 in the transplant room.

NOTE Confidence: 0.8595013

00:35:11.440 --> 00:35:13.186 Cell therapy program here at Yale,

NOTE Confidence: 0.8595013

00:35:13.190 --> 00:35:15.297 and he's going to go over some

NOTE Confidence: 0.8595013

00:35:15.297 --> 00:35:16.700 new and exciting transplant

NOTE Confidence: 0.8595013

00:35:16.700 --> 00:35:18.840 results from the ASH meeting.

NOTE Confidence: 0.80558455875

00:35:20.010 --> 00:35:21.278 Hello everyone and and

NOTE Confidence: 0.80558455875

00:35:21.278 --> 00:35:22.546 it's a Friday afternoon.

NOTE Confidence: 0.80558455875

00:35:22.550 --> 00:35:24.480 I promise I'll get you

NOTE Confidence: 0.80558455875

00:35:24.480 --> 00:35:26.940 guys out for lunch in time.

NOTE Confidence: 0.80558455875

00:35:26.940 --> 00:35:28.340 No conflicts of interest.

NOTE Confidence: 0.80558455875

00:35:28.340 --> 00:35:30.440 Here are my thoughts comments for

NOTE Confidence: 0.80558455875

00:35:30.506 --> 00:35:32.230 from the study investigators,

NOTE Confidence: 0.80558455875

00:35:32.230 --> 00:35:34.600 the study groups, and different

NOTE Confidence: 0.80558455875

00:35:34.600 --> 00:35:36.970 individuals who shared their slides.
NOTE Confidence: 0.80558455875

00:35:36.970 --> 00:35:39.560 The main objective of today's talk is
NOTE Confidence: 0.80558455875

00:35:39.560 --> 00:35:42.068 largely club under three main headings.
NOTE Confidence: 0.80558455875

00:35:42.070 --> 00:35:42.940 Yeah, as we all know,
NOTE Confidence: 0.80558455875

00:35:42.940 --> 00:35:44.053 allergenic transplantation as
NOTE Confidence: 0.80558455875

00:35:44.053 --> 00:35:46.650 a 70 year track record of cure,
NOTE Confidence: 0.80558455875

00:35:46.650 --> 00:35:47.882 but relapses do happen.
NOTE Confidence: 0.80558455875

00:35:47.882 --> 00:35:50.503 So I'm I'm going to present you some
NOTE Confidence: 0.80558455875

00:35:50.503 --> 00:35:52.639 data about the role of preemptive
NOTE Confidence: 0.80558455875

00:35:52.639 --> 00:35:54.080 maintenance post transplant.
NOTE Confidence: 0.80558455875

00:35:54.080 --> 00:35:55.580 One of the Achilles heel of
NOTE Confidence: 0.80558455875

00:35:55.580 --> 00:35:56.914 alleged extract point has been
NOTE Confidence: 0.80558455875

00:35:56.914 --> 00:35:58.309 graph to source disease normally
NOTE Confidence: 0.80558455875

00:35:58.309 --> 00:35:59.900 would present under 2 headings,
NOTE Confidence: 0.80558455875

00:35:59.900 --> 00:36:02.498 acute and chronic graft resource disease.
NOTE Confidence: 0.80558455875

00:36:02.500 --> 00:36:03.442 Based on the most recent data

NOTE Confidence: 0.80558455875
00:36:03.442 --> 00:36:04.380 that I'm going to present,
NOTE Confidence: 0.80558455875
00:36:04.380 --> 00:36:05.885 looks like you might have one drug
NOTE Confidence: 0.80558455875
00:36:05.885 --> 00:36:07.476 which is taking care of both of that.
NOTE Confidence: 0.80558455875
00:36:07.480 --> 00:36:08.860 So that's the phase three study
NOTE Confidence: 0.80558455875
00:36:08.860 --> 00:36:10.629 that I'm going to be talking about.
NOTE Confidence: 0.80558455875
00:36:10.630 --> 00:36:11.154 And finally,
NOTE Confidence: 0.80558455875
00:36:11.154 --> 00:36:13.949 I know it's the last talk of our CME series,
NOTE Confidence: 0.80558455875
00:36:13.950 --> 00:36:16.650 but throughout my life group discussion,
NOTE Confidence: 0.80558455875
00:36:16.650 --> 00:36:17.970 we've learned that, you know,
NOTE Confidence: 0.80558455875
00:36:17.970 --> 00:36:19.146 there are many novel,
NOTE Confidence: 0.80558455875
00:36:19.146 --> 00:36:20.322 exciting advances that drugs
NOTE Confidence: 0.80558455875
00:36:20.322 --> 00:36:21.350 are coming through.
NOTE Confidence: 0.80558455875
00:36:21.350 --> 00:36:23.226 But I'm here to convince you guys
NOTE Confidence: 0.80558455875
00:36:23.226 --> 00:36:24.809 that despite those drug advances,
NOTE Confidence: 0.80558455875
00:36:24.810 --> 00:36:26.634 allergenic stem cell transplant
NOTE Confidence: 0.80558455875

00:36:26.634 --> 00:36:28.490 is actually is at the forefront
NOTE Confidence: 0.80558455875

00:36:28.490 --> 00:36:30.273 and we anticipate a high number of
NOTE Confidence: 0.80558455875

00:36:30.273 --> 00:36:31.888 patients going forward to receive
NOTE Confidence: 0.80558455875

00:36:31.888 --> 00:36:33.180 other transplant because outcomes
NOTE Confidence: 0.80558455875

00:36:33.227 --> 00:36:34.747 have gotten significantly better.
NOTE Confidence: 0.80558455875

00:36:34.750 --> 00:36:38.082 And I'll bring about some data to
NOTE Confidence: 0.80558455875

00:36:38.082 --> 00:36:39.795 support that statement. Alright.
NOTE Confidence: 0.80558455875

00:36:39.795 --> 00:36:41.790 And the first study that I'm going
NOTE Confidence: 0.80558455875

00:36:41.790 --> 00:36:43.470 to be talking to you is,
NOTE Confidence: 0.80558455875

00:36:43.470 --> 00:36:45.892 is a study that was done across
NOTE Confidence: 0.80558455875

00:36:45.892 --> 00:36:48.230 from CFO which was using ID,
NOTE Confidence: 0.80558455875

00:36:48.230 --> 00:36:50.690 its two mutation sub group which
NOTE Confidence: 0.80558455875

00:36:50.772 --> 00:36:53.388 happens in about 20% of the cases,
NOTE Confidence: 0.80558455875

00:36:53.388 --> 00:36:54.426 20% of patients.
NOTE Confidence: 0.80558455875

00:36:54.430 --> 00:36:56.446 We all know that Doug Anderson
NOTE Confidence: 0.80558455875

00:36:56.446 --> 00:36:58.998 name is approved in mutant ideas

NOTE Confidence: 0.80558455875

00:36:58.998 --> 00:37:01.658 plus two types index subgroup.

NOTE Confidence: 0.80558455875

00:37:01.658 --> 00:37:04.202 Those with the last refractory AML

NOTE Confidence: 0.80558455875

00:37:04.202 --> 00:37:06.867 D or R is about 40% but there are

NOTE Confidence: 0.80558455875

00:37:06.867 --> 00:37:08.400 responses do not last long with the

NOTE Confidence: 0.80558455875

00:37:08.451 --> 00:37:10.512 median duration of response about 5.8 months.

NOTE Confidence: 0.80558455875

00:37:10.512 --> 00:37:12.258 So the group here actually tried

NOTE Confidence: 0.80558455875

00:37:12.258 --> 00:37:14.535 to do a maintenance concept post

NOTE Confidence: 0.80558455875

00:37:14.535 --> 00:37:16.167 transplant wherein they introduced

NOTE Confidence: 0.80558455875

00:37:16.167 --> 00:37:18.548 the drug post transplant from days 50

NOTE Confidence: 0.80558455875

00:37:18.548 --> 00:37:21.174 to 18120 at about 100 milligrams per day.

NOTE Confidence: 0.80558455875

00:37:21.180 --> 00:37:22.776 The plan was to give for about

NOTE Confidence: 0.80558455875

00:37:22.776 --> 00:37:24.334 two years and each cycle would

NOTE Confidence: 0.80558455875

00:37:24.334 --> 00:37:25.694 last for about 20-8 days.

NOTE Confidence: 0.80558455875

00:37:25.700 --> 00:37:26.800 It's a small group study.

NOTE Confidence: 0.80558455875

00:37:26.800 --> 00:37:28.064 The total was 15.

NOTE Confidence: 0.80558455875

00:37:28.064 --> 00:37:29.644 They included patients and had
NOTE Confidence: 0.80558455875

00:37:29.644 --> 00:37:31.866 a transparent CR1CR2 onward MRD
NOTE Confidence: 0.80558455875

00:37:31.866 --> 00:37:34.540 positive cases post alert CT as well.
NOTE Confidence: 0.80558455875

00:37:34.540 --> 00:37:35.191 In this study,
NOTE Confidence: 0.80558455875

00:37:35.191 --> 00:37:36.900 the median time to start the drug was
NOTE Confidence: 0.80558455875

00:37:36.900 --> 00:37:40.450 105 days. Download various craft.
NOTE Confidence: 0.80558455875

00:37:40.450 --> 00:37:42.138 Various GVHD and various
NOTE Confidence: 0.80558455875

00:37:42.138 --> 00:37:43.404 transparent relative conditionings.
NOTE Confidence: 0.80558455875

00:37:43.410 --> 00:37:45.150 The median age is population
NOTE Confidence: 0.80558455875

00:37:45.150 --> 00:37:47.573 with about 58 years and all great
NOTE Confidence: 0.80558455875

00:37:47.573 --> 00:37:49.619 adverse events during the study was
NOTE Confidence: 0.80558455875

00:37:49.619 --> 00:37:51.490 reported for the first two cycles,
NOTE Confidence: 0.80558455875

00:37:51.490 --> 00:37:55.254 whereas for grade 3 or higher for
NOTE Confidence: 0.80558455875

00:37:55.254 --> 00:37:56.710 subsequent cycles were reported.
NOTE Confidence: 0.80558455875

00:37:56.710 --> 00:37:57.690 In the first two cycles,
NOTE Confidence: 0.80558455875

00:37:57.690 --> 00:38:00.070 it's usually all of them was included.

NOTE Confidence: 0.80558455875
00:38:00.070 --> 00:38:01.945 The methodology used to monitor
NOTE Confidence: 0.80558455875
00:38:01.945 --> 00:38:04.670 for DS2 was a digital doctor PCR.
NOTE Confidence: 0.80558455875
00:38:04.670 --> 00:38:06.548 And as has been shown here,
NOTE Confidence: 0.80558455875
00:38:06.550 --> 00:38:08.167 if you focus on the right and
NOTE Confidence: 0.80558455875
00:38:08.167 --> 00:38:08.860 one of the
NOTE Confidence: 0.784485888095238
00:38:08.926 --> 00:38:10.798 commonest concern that we have of
NOTE Confidence: 0.784485888095238
00:38:10.798 --> 00:38:12.750 using these drugs is cytopenias.
NOTE Confidence: 0.784485888095238
00:38:12.750 --> 00:38:14.430 The risks of cytopenias, lymphopenia,
NOTE Confidence: 0.784485888095238
00:38:14.430 --> 00:38:16.128 anemia and neutropenia is was pretty
NOTE Confidence: 0.784485888095238
00:38:16.128 --> 00:38:18.107 modest and and it's it's not really
NOTE Confidence: 0.784485888095238
00:38:18.107 --> 00:38:19.948 significant for those of you use the
NOTE Confidence: 0.784485888095238
00:38:20.003 --> 00:38:21.984 drug in the pre transplant context that's
NOTE Confidence: 0.784485888095238
00:38:21.984 --> 00:38:23.848 that's a major issue but those are
NOTE Confidence: 0.784485888095238
00:38:23.848 --> 00:38:25.722 usually the people that have an abnormal
NOTE Confidence: 0.784485888095238
00:38:25.722 --> 00:38:27.510 marrow and the disease in association.
NOTE Confidence: 0.784485888095238

00:38:27.510 --> 00:38:29.470 So I was surprised to see the
NOTE Confidence: 0.784485888095238

00:38:29.470 --> 00:38:30.999 side opinions although existing
NOTE Confidence: 0.784485888095238

00:38:30.999 --> 00:38:32.984 wasn't significantly high and GI
NOTE Confidence: 0.784485888095238

00:38:32.984 --> 00:38:35.163 side effect was rather common side
NOTE Confidence: 0.784485888095238

00:38:35.163 --> 00:38:37.143 effect interestingly at least as was
NOTE Confidence: 0.784485888095238

00:38:37.150 --> 00:38:38.760 presented with the median follow-up
NOTE Confidence: 0.784485888095238

00:38:38.760 --> 00:38:41.444 of 17 months the one and two are
NOTE Confidence: 0.784485888095238

00:38:41.444 --> 00:38:43.472 progression free survival was about 100%.
NOTE Confidence: 0.784485888095238

00:38:43.480 --> 00:38:44.980 Common when we talk about maintenance,
NOTE Confidence: 0.784485888095238

00:38:44.980 --> 00:38:47.255 we talk about flip 3 limited studies.
NOTE Confidence: 0.784485888095238

00:38:47.260 --> 00:38:49.582 We're waiting on the full data of the BMT
NOTE Confidence: 0.784485888095238

00:38:49.582 --> 00:38:51.800 CTN three that used the three Nevada.
NOTE Confidence: 0.784485888095238

00:38:51.800 --> 00:38:53.440 But I think outside of that idea as
NOTE Confidence: 0.784485888095238

00:38:53.440 --> 00:38:55.151 to where we have targeted agents is
NOTE Confidence: 0.784485888095238

00:38:55.151 --> 00:38:56.714 an important subgroup and I thought
NOTE Confidence: 0.784485888095238

00:38:56.714 --> 00:38:58.250 this would be of meaningful practical

NOTE Confidence: 0.784485888095238

00:38:58.250 --> 00:38:59.758 use as we treat our patients.

NOTE Confidence: 0.772969496923077

00:39:02.270 --> 00:39:03.680 The other maintenance stadium going

NOTE Confidence: 0.772969496923077

00:39:03.680 --> 00:39:05.989 to talk about is a phase one study.

NOTE Confidence: 0.772969496923077

00:39:05.990 --> 00:39:08.470 Some of you might be aware that when

NOTE Confidence: 0.772969496923077

00:39:08.470 --> 00:39:10.502 the clients has also been integrated

NOTE Confidence: 0.772969496923077

00:39:10.502 --> 00:39:12.267 in the transplant preparative regimens.

NOTE Confidence: 0.772969496923077

00:39:12.270 --> 00:39:14.718 The study was published by Garcia

NOTE Confidence: 0.772969496923077

00:39:14.718 --> 00:39:16.350 and colleagues from Boston.

NOTE Confidence: 0.772969496923077

00:39:16.350 --> 00:39:17.885 What they're now presenting is

NOTE Confidence: 0.772969496923077

00:39:17.885 --> 00:39:19.746 when you integrate whether class to

NOTE Confidence: 0.772969496923077

00:39:19.746 --> 00:39:21.685 flow data and cell phone which is

NOTE Confidence: 0.772969496923077

00:39:21.685 --> 00:39:23.020 appropriate regiment that's commonly

NOTE Confidence: 0.772969496923077

00:39:23.020 --> 00:39:24.830 used in the transplantation context.

NOTE Confidence: 0.772969496923077

00:39:24.830 --> 00:39:27.845 There are trying to add the HMM and when

NOTE Confidence: 0.772969496923077

00:39:27.845 --> 00:39:31.539 it reflects as a maintenance post transplant.

NOTE Confidence: 0.772969496923077

00:39:31.540 --> 00:39:33.528 The last ticket put on really is
NOTE Confidence: 0.772969496923077

00:39:33.528 --> 00:39:35.385 focused on using is a Satanism
NOTE Confidence: 0.772969496923077

00:39:35.385 --> 00:39:37.395 maintenance and there are many many
NOTE Confidence: 0.772969496923077

00:39:37.395 --> 00:39:39.058 interesting reports in that regard.
NOTE Confidence: 0.772969496923077

00:39:39.060 --> 00:39:40.818 But the combination as you realize
NOTE Confidence: 0.772969496923077

00:39:40.818 --> 00:39:42.641 the doublets and triplets are making
NOTE Confidence: 0.772969496923077

00:39:42.641 --> 00:39:44.435 forays in the non transparent context.
NOTE Confidence: 0.772969496923077

00:39:44.440 --> 00:39:46.008 And I also see this now coming
NOTE Confidence: 0.772969496923077

00:39:46.008 --> 00:39:47.759 in the post transplant context.
NOTE Confidence: 0.772969496923077

00:39:47.760 --> 00:39:49.503 And this is one of those phase
NOTE Confidence: 0.772969496923077

00:39:49.503 --> 00:39:51.420 one study to identify the doses.
NOTE Confidence: 0.772969496923077

00:39:51.420 --> 00:39:53.373 So they started out with 400
NOTE Confidence: 0.772969496923077

00:39:53.373 --> 00:39:55.477 milligrams from Day 1 to 14 is the
NOTE Confidence: 0.772969496923077

00:39:55.477 --> 00:39:57.236 cycling was used at 36 milligrams
NOTE Confidence: 0.772969496923077

00:39:57.236 --> 00:39:59.419 per meter square on days one to five.
NOTE Confidence: 0.772969496923077

00:39:59.420 --> 00:40:00.631 A lot of user trials in the

NOTE Confidence: 0.772969496923077

00:40:00.631 --> 00:40:01.600 past have tried different.

NOTE Confidence: 0.772969496923077

00:40:01.600 --> 00:40:03.408 This is different days and and I think

NOTE Confidence: 0.772969496923077

00:40:03.408 --> 00:40:05.236 at least in this study they kind of

NOTE Confidence: 0.772969496923077

00:40:05.236 --> 00:40:06.948 narrowed it down to a slightly lower

NOTE Confidence: 0.772969496923077

00:40:06.948 --> 00:40:08.761 dose which with the hope that perhaps

NOTE Confidence: 0.772969496923077

00:40:08.770 --> 00:40:11.730 the combination is well tolerated.

NOTE Confidence: 0.772969496923077

00:40:11.730 --> 00:40:12.954 As was expected.

NOTE Confidence: 0.772969496923077

00:40:12.954 --> 00:40:15.624 You know, cytopenias worst thing.

NOTE Confidence: 0.772969496923077

00:40:15.624 --> 00:40:17.249 Neutropenia was 95%,

NOTE Confidence: 0.772969496923077

00:40:17.249 --> 00:40:18.416 thrombocytopenia was 91%.

NOTE Confidence: 0.772969496923077

00:40:18.416 --> 00:40:20.361 So cleverly the DLT definition

NOTE Confidence: 0.772969496923077

00:40:20.361 --> 00:40:21.929 that study was grateful.

NOTE Confidence: 0.772969496923077

00:40:21.930 --> 00:40:23.518 Looping or thrombocytopenia greater

NOTE Confidence: 0.772969496923077

00:40:23.518 --> 00:40:25.882 than two weeks with a median follow-up

NOTE Confidence: 0.772969496923077

00:40:25.882 --> 00:40:27.347 of 12 months follow-up regardless

NOTE Confidence: 0.772969496923077

00:40:27.347 --> 00:40:29.070 of the patient got maintenance.
NOTE Confidence: 0.772969496923077

00:40:29.070 --> 00:40:30.715 The one year progression free
NOTE Confidence: 0.772969496923077

00:40:30.715 --> 00:40:32.690 survival was in relapse report here.
NOTE Confidence: 0.772969496923077

00:40:32.690 --> 00:40:35.724 The OS was 70%, PFS was 57%.
NOTE Confidence: 0.772969496923077

00:40:35.724 --> 00:40:37.608 There was no non relapse mortality
NOTE Confidence: 0.772969496923077

00:40:37.608 --> 00:40:39.457 suggesting it's it's a safer combination
NOTE Confidence: 0.772969496923077

00:40:39.457 --> 00:40:41.910 to push you in the post transplant context.
NOTE Confidence: 0.772969496923077

00:40:41.910 --> 00:40:44.310 But relapse was still of concern
NOTE Confidence: 0.772969496923077

00:40:44.310 --> 00:40:45.910 despite using a doublet.
NOTE Confidence: 0.772969496923077

00:40:45.910 --> 00:40:47.788 Nomination in the post transplant context.
NOTE Confidence: 0.67735497125

00:40:50.530 --> 00:40:53.666 Now let's switch gears and talk about GVHD.
NOTE Confidence: 0.67735497125

00:40:53.670 --> 00:40:56.855 Now many of you know that calcination
NOTE Confidence: 0.67735497125

00:40:56.855 --> 00:40:58.684 based combination tachyons for
NOTE Confidence: 0.67735497125

00:40:58.684 --> 00:41:01.372 methotrexate has been a standard of care
NOTE Confidence: 0.67735497125

00:41:01.372 --> 00:41:04.068 for sorry for the last four decades.
NOTE Confidence: 0.67735497125

00:41:04.070 --> 00:41:06.206 So in order to explore more on how

NOTE Confidence: 0.67735497125

00:41:06.206 --> 00:41:09.090 we can optimize and identify the best

NOTE Confidence: 0.67735497125

00:41:09.090 --> 00:41:11.074 combination BMT CTN 1203 study ran A3

NOTE Confidence: 0.67735497125

00:41:11.074 --> 00:41:13.727 ARM study where in the the check to

NOTE Confidence: 0.67735497125

00:41:13.727 --> 00:41:15.299 conventional arm track methotrexate

NOTE Confidence: 0.67735497125

00:41:15.299 --> 00:41:17.055 with Bortezomib tack methotrexate

NOTE Confidence: 0.67735497125

00:41:17.055 --> 00:41:18.867 with the chemokine inhibitor.

NOTE Confidence: 0.67735497125

00:41:18.870 --> 00:41:20.690 Versus a full side arm,

NOTE Confidence: 0.67735497125

00:41:20.690 --> 00:41:23.511 the phase two study and the winner

NOTE Confidence: 0.67735497125

00:41:23.511 --> 00:41:26.312 of that study was the post I am

NOTE Confidence: 0.67735497125

00:41:26.312 --> 00:41:27.877 which we call the PCI.

NOTE Confidence: 0.67735497125

00:41:27.880 --> 00:41:30.022 This was then taken to a phase three study

NOTE Confidence: 0.67735497125

00:41:30.022 --> 00:41:31.897 where PCI tackled Amos and microphone.

NOTE Confidence: 0.67735497125

00:41:31.900 --> 00:41:34.312 It was compared against the historical

NOTE Confidence: 0.67735497125

00:41:34.312 --> 00:41:37.079 control which is stacked and methotrexate.

NOTE Confidence: 0.67735497125

00:41:37.080 --> 00:41:39.170 The study allowed reduced intensity

NOTE Confidence: 0.67735497125

00:41:39.170 --> 00:41:40.842 conditioning for individuals 18
NOTE Confidence: 0.67735497125

00:41:40.842 --> 00:41:43.092 years or older that have controlled
NOTE Confidence: 0.67735497125

00:41:43.092 --> 00:41:44.870 disease and and and peripheral
NOTE Confidence: 0.67735497125

00:41:44.870 --> 00:41:47.000 blood stem cell grafts were chosen.
NOTE Confidence: 0.67735497125

00:41:47.000 --> 00:41:49.688 Donors could be 6 out of 6L
NOTE Confidence: 0.67735497125

00:41:49.688 --> 00:41:52.477 matched or 7 to 8 or 8 sorry,
NOTE Confidence: 0.67735497125

00:41:52.480 --> 00:41:54.940 six out of 6 actually matched
NOTE Confidence: 0.67735497125

00:41:54.940 --> 00:41:57.095 donors or 11 antigen mismatched.
NOTE Confidence: 0.67735497125

00:41:57.095 --> 00:41:59.320 Unrelated donors were also aligned.
NOTE Confidence: 0.67735497125

00:41:59.320 --> 00:42:01.196 The primary endpoint of the study was
NOTE Confidence: 0.67735497125

00:42:01.196 --> 00:42:03.217 one year GRFS has been defined here,
NOTE Confidence: 0.67735497125

00:42:03.220 --> 00:42:04.996 even being defined as grade three
NOTE Confidence: 0.67735497125

00:42:04.996 --> 00:42:07.032 to four Q GVHD, chronic GVHD.
NOTE Confidence: 0.67735497125

00:42:07.032 --> 00:42:08.736 Requiring systemic must suppression,
NOTE Confidence: 0.67735497125

00:42:08.740 --> 00:42:09.748 relapse, progression, adapt,
NOTE Confidence: 0.67735497125

00:42:09.748 --> 00:42:11.764 and there were a few traditional

NOTE Confidence: 0.67735497125
00:42:11.764 --> 00:42:12.680 standard transplant,
NOTE Confidence: 0.67735497125
00:42:12.680 --> 00:42:15.450 Putin and secondary endpoints chosen.
NOTE Confidence: 0.67735497125
00:42:15.450 --> 00:42:19.517 Here's just a summary of what happened.
NOTE Confidence: 0.67735497125
00:42:19.520 --> 00:42:21.280 There was slightly more men.
NOTE Confidence: 0.67735497125
00:42:21.280 --> 00:42:23.574 The median Asia was about 66%.
NOTE Confidence: 0.67735497125
00:42:23.574 --> 00:42:26.332 Almost half of the people had kind
NOTE Confidence: 0.67735497125
00:42:26.332 --> 00:42:28.578 of performance score less than 90.
NOTE Confidence: 0.67735497125
00:42:28.580 --> 00:42:31.135 It had a wide range of hematologic
NOTE Confidence: 0.67735497125
00:42:31.135 --> 00:42:31.500 malignancies.
NOTE Confidence: 0.67735497125
00:42:31.500 --> 00:42:33.810 And and here's the percentage
NOTE Confidence: 0.67735497125
00:42:33.810 --> 00:42:35.196 of related unrelated,
NOTE Confidence: 0.67735497125
00:42:35.200 --> 00:42:37.064 unrelated donors with unrelated
NOTE Confidence: 0.67735497125
00:42:37.064 --> 00:42:39.394 donor being the Communist platform.
NOTE Confidence: 0.67735497125
00:42:39.400 --> 00:42:41.325 They did allow different regiments
NOTE Confidence: 0.67735497125
00:42:41.325 --> 00:42:42.480 to be chosen.
NOTE Confidence: 0.67735497125

00:42:42.480 --> 00:42:43.584 That is blue flu,
NOTE Confidence: 0.67735497125

00:42:43.584 --> 00:42:44.202 flu, mail.
NOTE Confidence: 0.67735497125

00:42:44.202 --> 00:42:46.938 To go with which perhaps in modern day
NOTE Confidence: 0.67735497125

00:42:46.938 --> 00:42:49.897 or some of the commonest options used.
NOTE Confidence: 0.67735497125

00:42:49.900 --> 00:42:51.636 Planned post transplant maintenance
NOTE Confidence: 0.67735497125

00:42:51.636 --> 00:42:54.240 therapies was used in about approximately
NOTE Confidence: 0.67735497125

00:42:54.301 --> 00:42:56.414 25% of the people in the post I am orsus,
NOTE Confidence: 0.67735497125

00:42:56.420 --> 00:42:59.210 22% in the non Siam.
NOTE Confidence: 0.67735497125

00:42:59.210 --> 00:43:01.646 The study did meet the primary endpoint,
NOTE Confidence: 0.67735497125

00:43:01.650 --> 00:43:03.588 the one year graft also source
NOTE Confidence: 0.67735497125

00:43:03.588 --> 00:43:05.299 disease relapse with survival was
NOTE Confidence: 0.67735497125

00:43:05.299 --> 00:43:07.079 superior with the post transplant
NOTE Confidence: 0.67735497125

00:43:07.079 --> 00:43:08.796 cyclophosphamide as has been shown
NOTE Confidence: 0.67735497125

00:43:08.796 --> 00:43:12.460 here with that has a ratio of 0.64.
NOTE Confidence: 0.67735497125

00:43:12.460 --> 00:43:15.727 The rates of great three to four Q GVHD
NOTE Confidence: 0.67735497125

00:43:15.727 --> 00:43:18.315 was 6.3% versus 14.7% suggesting post

NOTE Confidence: 0.67735497125

00:43:18.315 --> 00:43:21.185 size able to decrease graph resource

NOTE Confidence: 0.67735497125

00:43:21.185 --> 00:43:24.599 disease and same with chronic graft

NOTE Confidence: 0.67735497125

00:43:24.599 --> 00:43:26.306 associated requiring suppression.

NOTE Confidence: 0.67735497125

00:43:26.310 --> 00:43:28.940 The Posi arm had about 12.5%

NOTE Confidence: 0.67735497125

00:43:28.940 --> 00:43:30.900 methotrexate armor 25% basically

NOTE Confidence: 0.67735497125

00:43:30.900 --> 00:43:34.072 halving the risk of chronic GVHD

NOTE Confidence: 0.67735497125

00:43:34.072 --> 00:43:36.440 requiring suppression and importantly

NOTE Confidence: 0.67735497125

00:43:36.440 --> 00:43:38.600 GVHD prelapsarian survival was

NOTE Confidence: 0.67735497125

00:43:38.600 --> 00:43:41.780 almost 62% compared to 45% off.

NOTE Confidence: 0.67735497125

00:43:41.780 --> 00:43:43.844 Is concerned that when using your

NOTE Confidence: 0.67735497125

00:43:43.844 --> 00:43:45.840 depleting agents there's the GL impact.

NOTE Confidence: 0.67735497125

00:43:45.840 --> 00:43:48.066 Gmail is impacted as is shown here.

NOTE Confidence: 0.67735497125

00:43:48.070 --> 00:43:50.415 It seems to be disentangled and

NOTE Confidence: 0.67735497125

00:43:50.415 --> 00:43:52.125 relapse and progression was not a

NOTE Confidence: 0.67735497125

00:43:52.125 --> 00:43:53.957 concern with the application of

NOTE Confidence: 0.67735497125

00:43:53.957 --> 00:43:55.331 post transplant cyclophosphamide
NOTE Confidence: 0.67735497125

00:43:55.331 --> 00:43:57.163 compared to tack methotrexate.
NOTE Confidence: 0.67735497125

00:43:57.170 --> 00:43:58.610 Treatment related mortality,
NOTE Confidence: 0.67735497125

00:43:58.610 --> 00:44:00.034 it's 12% if, if,
NOTE Confidence: 0.67735497125

00:44:00.034 --> 00:44:00.266 if,
NOTE Confidence: 0.67735497125

00:44:00.266 --> 00:44:01.890 if you all read our books back
NOTE Confidence: 0.67735497125

00:44:01.952 --> 00:44:03.752 about 10-15 years or treatment
NOTE Confidence: 0.67735497125

00:44:03.752 --> 00:44:05.552 later mortality transplant used to
NOTE Confidence: 0.758474324090909

00:44:05.607 --> 00:44:08.220 be about 2530%. Now that number has
NOTE Confidence: 0.758474324090909

00:44:08.220 --> 00:44:10.390 come down significantly and the
NOTE Confidence: 0.758474324090909

00:44:10.466 --> 00:44:12.902 overall survival in this arm was
NOTE Confidence: 0.758474324090909

00:44:12.902 --> 00:44:16.195 about 77% of interest to note here
NOTE Confidence: 0.758474324090909

00:44:16.195 --> 00:44:17.827 is that overall survival at this
NOTE Confidence: 0.758474324090909

00:44:17.827 --> 00:44:19.407 time point actually didn't change,
NOTE Confidence: 0.758474324090909

00:44:19.410 --> 00:44:21.780 it was 77%, also 72%.
NOTE Confidence: 0.758474324090909

00:44:21.780 --> 00:44:25.378 But remember the study endpoint was GRFS.

NOTE Confidence: 0.758474324090909
00:44:25.380 --> 00:44:26.689 So then people tend to ask what
NOTE Confidence: 0.758474324090909
00:44:26.689 --> 00:44:27.791 what about the secondary outcomes
NOTE Confidence: 0.758474324090909
00:44:27.791 --> 00:44:29.279 in highlighted in purple are the
NOTE Confidence: 0.758474324090909
00:44:29.279 --> 00:44:30.466 ones that were not significant
NOTE Confidence: 0.758474324090909
00:44:30.466 --> 00:44:31.971 and in the dark bright yellow is
NOTE Confidence: 0.758474324090909
00:44:31.980 --> 00:44:33.680 the ones that are significant.
NOTE Confidence: 0.758474324090909
00:44:33.680 --> 00:44:35.500 When your survival didn't change,
NOTE Confidence: 0.758474324090909
00:44:35.500 --> 00:44:37.200 when your disease with survival
NOTE Confidence: 0.758474324090909
00:44:37.200 --> 00:44:39.704 didn't changed, TRM did not change.
NOTE Confidence: 0.758474324090909
00:44:39.704 --> 00:44:40.160 Statistically,
NOTE Confidence: 0.758474324090909
00:44:40.160 --> 00:44:41.705 cumulative incidence or Q GVHD
NOTE Confidence: 0.758474324090909
00:44:41.705 --> 00:44:43.959 grades two to four did not change.
NOTE Confidence: 0.758474324090909
00:44:43.960 --> 00:44:46.216 But what did change though is
NOTE Confidence: 0.758474324090909
00:44:46.216 --> 00:44:48.032 cumulative incidence of acute GBS
NOTE Confidence: 0.758474324090909
00:44:48.032 --> 00:44:50.078 day 100 grades three to four.
NOTE Confidence: 0.758474324090909

00:44:50.080 --> 00:44:51.752 You know if you have grade one and
NOTE Confidence: 0.758474324090909

00:44:51.752 --> 00:44:53.900 two GSD most times it's not of a
NOTE Confidence: 0.758474324090909

00:44:53.900 --> 00:44:55.225 significant concern, the higher grade.
NOTE Confidence: 0.758474324090909

00:44:55.225 --> 00:44:56.755 It's the other one we are
NOTE Confidence: 0.758474324090909

00:44:56.755 --> 00:44:58.029 concerned about with the post.
NOTE Confidence: 0.758474324090909

00:44:58.030 --> 00:45:01.640 I was 6.3% compared to about 14.7%.
NOTE Confidence: 0.758474324090909

00:45:01.640 --> 00:45:04.390 Similarly chronic GVHD at 12
NOTE Confidence: 0.758474324090909

00:45:04.390 --> 00:45:07.234 months was 21% compared to 35%.
NOTE Confidence: 0.758474324090909

00:45:07.234 --> 00:45:09.850 The salary carrier was slightly slower
NOTE Confidence: 0.758474324090909

00:45:09.931 --> 00:45:12.679 both for neutrophils and platelets and
NOTE Confidence: 0.758474324090909

00:45:12.679 --> 00:45:15.675 as is commonly expected and and the
NOTE Confidence: 0.758474324090909

00:45:15.675 --> 00:45:17.600 risk of breakthrough infections will
NOTE Confidence: 0.758474324090909

00:45:17.600 --> 00:45:19.879 not not significantly higher at 12
NOTE Confidence: 0.758474324090909

00:45:19.879 --> 00:45:23.269 months now is the risk of CMV reactivation,
NOTE Confidence: 0.758474324090909

00:45:23.270 --> 00:45:24.042 importantly immunosuppression
NOTE Confidence: 0.758474324090909

00:45:24.042 --> 00:45:25.586 free survival at one.

NOTE Confidence: 0.758474324090909
00:45:25.590 --> 00:45:25.892 Yeah,
NOTE Confidence: 0.758474324090909
00:45:25.892 --> 00:45:28.610 was was better off as has been shown here.
NOTE Confidence: 0.73004946875
00:45:30.740 --> 00:45:32.108 The other other question
NOTE Confidence: 0.73004946875
00:45:32.108 --> 00:45:34.030 people ask is about, you know,
NOTE Confidence: 0.73004946875
00:45:34.030 --> 00:45:35.955 what's the risk of graft failure or
NOTE Confidence: 0.73004946875
00:45:35.955 --> 00:45:37.858 how does the chimerism play out?
NOTE Confidence: 0.73004946875
00:45:37.860 --> 00:45:39.012 As shown here, they have definitions
NOTE Confidence: 0.73004946875
00:45:39.012 --> 00:45:40.160 for what's the full chimerism?
NOTE Confidence: 0.73004946875
00:45:40.160 --> 00:45:41.309 Mixed graph projections.
NOTE Confidence: 0.73004946875
00:45:41.309 --> 00:45:42.841 There's really no significant
NOTE Confidence: 0.73004946875
00:45:42.841 --> 00:45:44.347 differences based on that
NOTE Confidence: 0.73004946875
00:45:44.347 --> 00:45:45.877 between the two treatment arms.
NOTE Confidence: 0.827247843333333
00:45:48.950 --> 00:45:51.308 Specifically people ask that, you know,
NOTE Confidence: 0.827247843333333
00:45:51.310 --> 00:45:53.032 this is making significant progress in
NOTE Confidence: 0.827247843333333
00:45:53.032 --> 00:45:55.088 the field of acute and chronic GVHD.
NOTE Confidence: 0.827247843333333

00:45:55.090 --> 00:45:56.616 Does it have any other side effects?
NOTE Confidence: 0.8272478433333333

00:45:56.620 --> 00:45:58.828 Well, you know the risk of acute or
NOTE Confidence: 0.8272478433333333

00:45:58.828 --> 00:46:00.829 chronic GVHD was significantly lower,
NOTE Confidence: 0.8272478433333333

00:46:00.830 --> 00:46:02.654 but they did come up a concern about
NOTE Confidence: 0.8272478433333333

00:46:02.654 --> 00:46:04.249 some organ failure and we're looking
NOTE Confidence: 0.8272478433333333

00:46:04.249 --> 00:46:06.236 for the full manuscript to see which
NOTE Confidence: 0.8272478433333333

00:46:06.236 --> 00:46:07.766 particular organs were affected as
NOTE Confidence: 0.8272478433333333

00:46:07.766 --> 00:46:09.872 it was slightly higher in the post
NOTE Confidence: 0.8272478433333333

00:46:09.872 --> 00:46:10.754 transplant cyclophosphamide arm
NOTE Confidence: 0.8272478433333333

00:46:10.754 --> 00:46:12.180 compared to the conventional care.
NOTE Confidence: 0.6652379452

00:46:15.600 --> 00:46:17.798 In summary, you know the superior GRS
NOTE Confidence: 0.6652379452

00:46:17.798 --> 00:46:20.377 went to the reduced even and Q GVHD led
NOTE Confidence: 0.6652379452

00:46:20.377 --> 00:46:23.097 to the post I am winning in this truck.
NOTE Confidence: 0.6652379452

00:46:23.100 --> 00:46:24.705 There was no increase in
NOTE Confidence: 0.6652379452

00:46:24.705 --> 00:46:25.668 relapse slash progressive,
NOTE Confidence: 0.6652379452

00:46:25.670 --> 00:46:27.840 which is critical importance to our people.

NOTE Confidence: 0.6652379452

00:46:27.840 --> 00:46:29.520 There was slightly delayed

NOTE Confidence: 0.6652379452

00:46:29.520 --> 00:46:30.360 hematopoietic recovery.

NOTE Confidence: 0.6652379452

00:46:30.360 --> 00:46:32.340 There was more grade 2 GI

NOTE Confidence: 0.6652379452

00:46:32.340 --> 00:46:34.140 events in the infection forms,

NOTE Confidence: 0.6652379452

00:46:34.140 --> 00:46:36.366 but they're mostly in the first month.

NOTE Confidence: 0.6652379452

00:46:36.370 --> 00:46:37.866 Based on the findings,

NOTE Confidence: 0.6652379452

00:46:37.866 --> 00:46:40.110 the field is slowly moving towards

NOTE Confidence: 0.6652379452

00:46:40.176 --> 00:46:42.206 the option of using postai as a

NOTE Confidence: 0.6652379452

00:46:42.210 --> 00:46:44.855 reduced intensity conditioning GVS 3

NOTE Confidence: 0.6652379452

00:46:44.855 --> 00:46:46.971 prophylactic options going forwards

NOTE Confidence: 0.6652379452

00:46:46.971 --> 00:46:49.688 in patients who are well matched.

NOTE Confidence: 0.6652379452

00:46:49.690 --> 00:46:50.865 There there are ongoing studies

NOTE Confidence: 0.6652379452

00:46:50.865 --> 00:46:52.352 to look and look for suitable

NOTE Confidence: 0.6652379452

00:46:52.352 --> 00:46:53.900 biomarkers and those will be coming

NOTE Confidence: 0.6652379452

00:46:53.900 --> 00:46:55.450 out over the next few months.

NOTE Confidence: 0.67660730944

00:46:58.610 --> 00:46:59.682 In that is available,
NOTE Confidence: 0.67660730944

00:46:59.682 --> 00:47:01.633 who's one of our leaders in the
NOTE Confidence: 0.67660730944

00:47:01.633 --> 00:47:03.367 leukemia program asked me to condense
NOTE Confidence: 0.67660730944

00:47:03.367 --> 00:47:05.607 some of the TCP slides with the ash.
NOTE Confidence: 0.67660730944

00:47:05.610 --> 00:47:07.580 Hematology slides because those are
NOTE Confidence: 0.67660730944

00:47:07.580 --> 00:47:09.550 are really practice changing here.
NOTE Confidence: 0.67660730944

00:47:09.550 --> 00:47:11.326 I'm presenting a study that's called
NOTE Confidence: 0.67660730944

00:47:11.326 --> 00:47:13.553 the CRF study that's Seropian was the
NOTE Confidence: 0.67660730944

00:47:13.553 --> 00:47:15.527 principal investigator on site for this.
NOTE Confidence: 0.67660730944

00:47:15.530 --> 00:47:16.885 This was a multicenter pivotal
NOTE Confidence: 0.67660730944

00:47:16.885 --> 00:47:18.701 phase three study of ISOMAP which is
NOTE Confidence: 0.67660730944

00:47:18.701 --> 00:47:20.341 going to talk to you about prior to
NOTE Confidence: 0.67660730944

00:47:20.397 --> 00:47:22.127 allogeneic stem cell transplant versus
NOTE Confidence: 0.67660730944

00:47:22.127 --> 00:47:23.857 conventional care in older patients
NOTE Confidence: 0.67660730944

00:47:23.860 --> 00:47:25.810 with acute relapse refractory leukemia.
NOTE Confidence: 0.67660730944

00:47:25.810 --> 00:47:27.934 Remember the majority of the patients

NOTE Confidence: 0.67660730944

00:47:27.934 --> 00:47:30.070 actually don't get to transplant.

NOTE Confidence: 0.67660730944

00:47:30.070 --> 00:47:31.834 Look at the median age for these

NOTE Confidence: 0.67660730944

00:47:31.834 --> 00:47:33.208 patients that developed leukemia is

NOTE Confidence: 0.67660730944

00:47:33.208 --> 00:47:35.332 somewhere around late 60s, early 70s.

NOTE Confidence: 0.67660730944

00:47:35.332 --> 00:47:37.296 And they're transplant ineligible.

NOTE Confidence: 0.67660730944

00:47:37.300 --> 00:47:38.890 So in that patient population

NOTE Confidence: 0.67660730944

00:47:38.890 --> 00:47:41.578 while we were at multiple new drug

NOTE Confidence: 0.67660730944

00:47:41.578 --> 00:47:43.138 developments transplanted historically

NOTE Confidence: 0.67660730944

00:47:43.138 --> 00:47:44.698 considered not suitable.

NOTE Confidence: 0.67660730944

00:47:44.700 --> 00:47:45.816 So into that domain,

NOTE Confidence: 0.67660730944

00:47:45.816 --> 00:47:47.896 this trial is trying to now make

NOTE Confidence: 0.67660730944

00:47:47.896 --> 00:47:49.611 headways with some interesting results

NOTE Confidence: 0.67660730944

00:47:49.611 --> 00:47:52.267 as I'm going to show to you all here.

NOTE Confidence: 0.747278952

00:47:55.730 --> 00:47:57.782 As I was mentioning last, in fact,

NOTE Confidence: 0.747278952

00:47:57.782 --> 00:48:00.428 Emilyn generally has got poor prognosis.

NOTE Confidence: 0.747278952

00:48:00.430 --> 00:48:01.478 On top of that,
NOTE Confidence: 0.747278952

00:48:01.478 --> 00:48:04.570 if you add old rays it makes it complicated.
NOTE Confidence: 0.747278952

00:48:04.570 --> 00:48:06.010 There are several reasons for that.
NOTE Confidence: 0.747278952

00:48:06.010 --> 00:48:07.350 Historically always believed intensive
NOTE Confidence: 0.747278952

00:48:07.350 --> 00:48:09.025 induction and accessory to keep
NOTE Confidence: 0.747278952

00:48:09.025 --> 00:48:10.227 permission going for long term.
NOTE Confidence: 0.747278952

00:48:10.230 --> 00:48:12.118 But most of these patients are not able
NOTE Confidence: 0.747278952

00:48:12.118 --> 00:48:14.128 to tolerate it and even if they tolerate it,
NOTE Confidence: 0.747278952

00:48:14.130 --> 00:48:15.894 the toxicities are higher if you
NOTE Confidence: 0.747278952

00:48:15.894 --> 00:48:18.290 continue to long terms and that leads
NOTE Confidence: 0.747278952

00:48:18.290 --> 00:48:20.230 to substantial treatment related mortality.
NOTE Confidence: 0.747278952

00:48:20.230 --> 00:48:21.850 Now since transplant is a higher
NOTE Confidence: 0.747278952

00:48:21.850 --> 00:48:22.930 intensity of treatment compared
NOTE Confidence: 0.747278952

00:48:22.981 --> 00:48:24.246 to the non transparent option,
NOTE Confidence: 0.747278952

00:48:24.250 --> 00:48:27.364 the term tends to go up in the population.
NOTE Confidence: 0.747278952

00:48:27.370 --> 00:48:31.482 However we are able to get some of those.

NOTE Confidence: 0.747278952

00:48:31.482 --> 00:48:34.080 Patients who have relapsed or practicing

NOTE Confidence: 0.747278952

00:48:34.158 --> 00:48:36.950 at back into remission and one of the.

NOTE Confidence: 0.747278952

00:48:36.950 --> 00:48:39.176 Conventions that we tend to fall in

NOTE Confidence: 0.747278952

00:48:39.176 --> 00:48:41.258 relapse refractory AML is we we tend

NOTE Confidence: 0.747278952

00:48:41.258 --> 00:48:42.866 not to transplant those patients in

NOTE Confidence: 0.747278952

00:48:42.928 --> 00:48:44.770 active disease because you know back

NOTE Confidence: 0.747278952

00:48:44.770 --> 00:48:47.324 maybe prior to 2000 when we used to

NOTE Confidence: 0.747278952

00:48:47.324 --> 00:48:49.274 do labs attracts AML who had active

NOTE Confidence: 0.747278952

00:48:49.274 --> 00:48:50.730 disease when the data is normal drugs

NOTE Confidence: 0.747278952

00:48:50.779 --> 00:48:52.179 though you know risk of relapse was

NOTE Confidence: 0.747278952

00:48:52.179 --> 00:48:53.587 pretty high in the Tiana was high.

NOTE Confidence: 0.747278952

00:48:53.590 --> 00:48:55.900 So based on that there are multiple

NOTE Confidence: 0.747278952

00:48:55.900 --> 00:48:57.286 novel drug development strategies

NOTE Confidence: 0.747278952

00:48:57.286 --> 00:48:58.606 that have come on.

NOTE Confidence: 0.747278952

00:48:58.610 --> 00:49:00.158 But what I have is not trying to do

NOTE Confidence: 0.747278952

00:49:00.158 --> 00:49:02.074 is trying to address the question
NOTE Confidence: 0.747278952

00:49:02.074 --> 00:49:02.750 slightly differently.
NOTE Confidence: 0.747278952

00:49:02.750 --> 00:49:04.646 So first of all, what is our map?
NOTE Confidence: 0.747278952

00:49:04.650 --> 00:49:07.548 Ahmad is basically a combination of things.
NOTE Confidence: 0.747278952

00:49:07.550 --> 00:49:09.986 They have a CD45 antibody that's
NOTE Confidence: 0.747278952

00:49:09.986 --> 00:49:12.101 conjugated to radioactive iodine and
NOTE Confidence: 0.747278952

00:49:12.101 --> 00:49:14.615 it is designed to deliver targeted
NOTE Confidence: 0.747278952

00:49:14.615 --> 00:49:16.706 myeloablative radiation dose to the
NOTE Confidence: 0.747278952

00:49:16.706 --> 00:49:18.626 hematopoietic cells and immune cells
NOTE Confidence: 0.747278952

00:49:18.630 --> 00:49:20.500 and then supplemented with reduced
NOTE Confidence: 0.747278952

00:49:20.500 --> 00:49:21.622 intensity conditioning priority
NOTE Confidence: 0.747278952

00:49:21.622 --> 00:49:23.430 analogy and stem cell transplant.
NOTE Confidence: 0.747278952

00:49:23.430 --> 00:49:24.726 Remember good old days when we
NOTE Confidence: 0.747278952

00:49:24.726 --> 00:49:25.590 used to do transplant,
NOTE Confidence: 0.747278952

00:49:25.590 --> 00:49:27.585 we used to use radiation based regimens,
NOTE Confidence: 0.747278952

00:49:27.590 --> 00:49:28.694 TBI kind of.

NOTE Confidence: 0.747278952

00:49:28.694 --> 00:49:31.270 While it's useful to suppress your immune

NOTE Confidence: 0.747278952

00:49:31.347 --> 00:49:34.077 system and radical Kenya and the narrow,

NOTE Confidence: 0.747278952

00:49:34.080 --> 00:49:36.162 it can cause significant argument toxicity

NOTE Confidence: 0.747278952

00:49:36.162 --> 00:49:38.440 because it's a total body radiation.

NOTE Confidence: 0.747278952

00:49:38.440 --> 00:49:39.810 Here they're trying to develop

NOTE Confidence: 0.747278952

00:49:39.810 --> 00:49:41.180 targeted radiation to leukemia cells,

NOTE Confidence: 0.747278952

00:49:41.180 --> 00:49:42.596 bone marrow stem cells,

NOTE Confidence: 0.747278952

00:49:42.596 --> 00:49:44.366 to address the primary problem

NOTE Confidence: 0.747278952

00:49:44.366 --> 00:49:46.148 of cute myeloid leukemia.

NOTE Confidence: 0.747278952

00:49:46.150 --> 00:49:47.918 With induction and conditioning,

NOTE Confidence: 0.747278952

00:49:47.918 --> 00:49:50.787 the hope here is that usage of this

NOTE Confidence: 0.747278952

00:49:50.787 --> 00:49:52.320 drug would allow rapid access to bone

NOTE Confidence: 0.747278952

00:49:52.367 --> 00:49:54.132 marrow transplant for multiple patients

NOTE Confidence: 0.747278952

00:49:54.132 --> 00:49:55.544 who relapsed refractory phenotype.

NOTE Confidence: 0.747278952

00:49:55.550 --> 00:49:57.242 So this was a prospective randomized

NOTE Confidence: 0.747278952

00:49:57.242 --> 00:49:59.409 strain study which is a phase three
NOTE Confidence: 0.747278952

00:49:59.409 --> 00:50:00.729 study exclusively for patient
NOTE Confidence: 0.747278952

00:50:00.729 --> 00:50:02.662 populations greater than 55 to compare
NOTE Confidence: 0.747278952

00:50:02.662 --> 00:50:04.142 rates of durable complete remissions
NOTE Confidence: 0.747278952

00:50:04.142 --> 00:50:05.996 that would last greater than 180
NOTE Confidence: 0.747278952

00:50:05.996 --> 00:50:07.252 days following initial complete
NOTE Confidence: 0.747278952

00:50:07.252 --> 00:50:08.509 remission between the two arms.
NOTE Confidence: 0.747278952

00:50:08.510 --> 00:50:10.364 So the study was randomized for
NOTE Confidence: 0.747278952

00:50:10.364 --> 00:50:12.054 IMAp followed by transplant versus
NOTE Confidence: 0.747278952

00:50:12.054 --> 00:50:13.646 physicians choice of conventional
NOTE Confidence: 0.747278952

00:50:13.646 --> 00:50:15.636 care for transplant and physicians.
NOTE Confidence: 0.747278952

00:50:15.640 --> 00:50:17.580 The Commission came included more
NOTE Confidence: 0.747278952

00:50:17.580 --> 00:50:19.897 than 20 different drugs that reflect
NOTE Confidence: 0.747278952

00:50:19.897 --> 00:50:20.884 on contemporary practice,
NOTE Confidence: 0.747278952

00:50:20.884 --> 00:50:22.569 including the BCL 2 inhibitor,
NOTE Confidence: 0.747278952

00:50:22.570 --> 00:50:25.730 split three inhibitors, etc.

NOTE Confidence: 0.747278952

00:50:25.730 --> 00:50:29.006 Ohh here's how the study design goes.

NOTE Confidence: 0.747278952

00:50:29.010 --> 00:50:30.310 People have relapsed practice

NOTE Confidence: 0.747278952

00:50:30.310 --> 00:50:31.610 phenotype greater than 55,

NOTE Confidence: 0.747278952

00:50:31.610 --> 00:50:32.938 randomized 1 to one.

NOTE Confidence: 0.747278952

00:50:32.938 --> 00:50:34.930 I am mapped to conventional care.

NOTE Confidence: 0.747278952

00:50:34.930 --> 00:50:36.370 Well then look for whether they're

NOTE Confidence: 0.747278952

00:50:36.370 --> 00:50:38.008 here or not and if it's a CR,

NOTE Confidence: 0.747278952

00:50:38.010 --> 00:50:39.120 what's the duration of CR

NOTE Confidence: 0.747278952

00:50:39.120 --> 00:50:40.230 whether the last six months

NOTE Confidence: 0.808253554166667

00:50:40.276 --> 00:50:42.652 or not. And that's the pre specified primary

NOTE Confidence: 0.808253554166667

00:50:42.652 --> 00:50:44.570 endpoint lasting greater than 180 days.

NOTE Confidence: 0.808253554166667

00:50:44.570 --> 00:50:46.628 Whereas with the conventional care arm

NOTE Confidence: 0.808253554166667

00:50:46.630 --> 00:50:49.110 depends whether they get into CR no CR.

NOTE Confidence: 0.808253554166667

00:50:49.110 --> 00:50:51.062 If they're the CR then they could go

NOTE Confidence: 0.808253554166667

00:50:51.062 --> 00:50:53.208 to the standard of care transplant.

NOTE Confidence: 0.808253554166667

00:50:53.210 --> 00:50:54.896 Our standard of care physicians choice.

NOTE Confidence: 0.812096425714286

00:50:57.210 --> 00:51:00.978 This, this concept of drug delivery

NOTE Confidence: 0.812096425714286

00:51:00.978 --> 00:51:02.456 needs hospitalization slightly earlier

NOTE Confidence: 0.812096425714286

00:51:02.456 --> 00:51:04.722 than what we would normally do in the

NOTE Confidence: 0.812096425714286

00:51:04.722 --> 00:51:06.186 context of a bone marrow transplant.

NOTE Confidence: 0.812096425714286

00:51:06.190 --> 00:51:08.270 So those patients were admitted

NOTE Confidence: 0.812096425714286

00:51:08.270 --> 00:51:11.398 around day 19 to get a test dose.

NOTE Confidence: 0.812096425714286

00:51:11.400 --> 00:51:13.315 After radioactive iodine and then

NOTE Confidence: 0.812096425714286

00:51:13.315 --> 00:51:16.261 they have to be kept in the hospital

NOTE Confidence: 0.812096425714286

00:51:16.261 --> 00:51:18.744 for a few days until the body

NOTE Confidence: 0.812096425714286

00:51:18.744 --> 00:51:20.954 eliminates all the radioactive doses.

NOTE Confidence: 0.812096425714286

00:51:20.960 --> 00:51:23.624 The then the data is then sent across to

NOTE Confidence: 0.812096425714286

00:51:23.624 --> 00:51:25.844 develop a therapeutic dose of the ILAB

NOTE Confidence: 0.812096425714286

00:51:25.844 --> 00:51:28.379 which is then given around day minus 12.

NOTE Confidence: 0.812096425714286

00:51:28.380 --> 00:51:30.516 You wait for about 8 days

NOTE Confidence: 0.812096425714286

00:51:30.520 --> 00:51:31.960 for that to take effect.

NOTE Confidence: 0.812096425714286

00:51:31.960 --> 00:51:33.976 Remember these are people who have

NOTE Confidence: 0.812096425714286

00:51:33.976 --> 00:51:35.669 active glass and activities coming

NOTE Confidence: 0.812096425714286

00:51:35.669 --> 00:51:37.678 into this this drug would you know

NOTE Confidence: 0.812096425714286

00:51:37.678 --> 00:51:39.292 Oblate most of those patients and

NOTE Confidence: 0.812096425714286

00:51:39.292 --> 00:51:41.324 then you go and use the principles of.

NOTE Confidence: 0.812096425714286

00:51:41.324 --> 00:51:43.298 Transplant just to use low dose of

NOTE Confidence: 0.812096425714286

00:51:43.298 --> 00:51:45.128 immuno ablation with fludarabine and

NOTE Confidence: 0.812096425714286

00:51:45.128 --> 00:51:46.993 TBI which lymphodepletion and also

NOTE Confidence: 0.812096425714286

00:51:46.993 --> 00:51:48.981 eradicate some of the disease followed

NOTE Confidence: 0.812096425714286

00:51:48.981 --> 00:51:50.940 by hematopoietic stem cell rescue and

NOTE Confidence: 0.812096425714286

00:51:50.940 --> 00:51:53.670 the option of GST prophylaxis is tactile

NOTE Confidence: 0.812096425714286

00:51:53.670 --> 00:51:57.760 limus cyclist form with microphone.

NOTE Confidence: 0.812096425714286

00:51:57.760 --> 00:51:59.040 Here's the concept now.

NOTE Confidence: 0.812096425714286

00:51:59.040 --> 00:52:00.640 Equal number of patients randomized.

NOTE Confidence: 0.812096425714286

00:52:00.640 --> 00:52:02.760 I'm unconventional.

NOTE Confidence: 0.812096425714286

00:52:02.760 --> 00:52:05.104 Case 767766 patients received
NOTE Confidence: 0.812096425714286

00:52:05.104 --> 00:52:05.960 therapeutic dose.
NOTE Confidence: 0.812096425714286

00:52:05.960 --> 00:52:07.815 66 were able to get a transplant.
NOTE Confidence: 0.812096425714286

00:52:07.820 --> 00:52:09.140 Per protocol analysis,
NOTE Confidence: 0.812096425714286

00:52:09.140 --> 00:52:10.460 59 were eligible.
NOTE Confidence: 0.812096425714286

00:52:10.460 --> 00:52:11.204 In contrast,
NOTE Confidence: 0.812096425714286

00:52:11.204 --> 00:52:13.808 a number of people in the conventional
NOTE Confidence: 0.812096425714286

00:52:13.808 --> 00:52:16.574 care that were able to get to CR was 14.
NOTE Confidence: 0.812096425714286

00:52:16.580 --> 00:52:18.629 Not able to get to CR was 62.
NOTE Confidence: 0.812096425714286

00:52:18.629 --> 00:52:20.621 For those who got to CR and were
NOTE Confidence: 0.812096425714286

00:52:20.621 --> 00:52:22.141 fourteen of them were all fourteen
NOTE Confidence: 0.812096425714286

00:52:22.141 --> 00:52:23.941 were able to go to transplant those
NOTE Confidence: 0.812096425714286

00:52:23.941 --> 00:52:26.190 who did not get to CR of 6218.
NOTE Confidence: 0.812096425714286

00:52:26.190 --> 00:52:28.200 Did not receive any further care.
NOTE Confidence: 0.812096425714286

00:52:28.200 --> 00:52:29.910 Likely went on to receive what
NOTE Confidence: 0.812096425714286

00:52:29.910 --> 00:52:31.440 you call palliative care options

NOTE Confidence: 0.812096425714286
00:52:31.440 --> 00:52:32.768 or no further treatment.
NOTE Confidence: 0.812096425714286
00:52:32.770 --> 00:52:33.866 Crossed over to IMAF.
NOTE Confidence: 0.812096425714286
00:52:33.866 --> 00:52:35.822 The costs over was allowed for people
NOTE Confidence: 0.812096425714286
00:52:35.822 --> 00:52:37.593 who did not reach CR after having
NOTE Confidence: 0.812096425714286
00:52:37.593 --> 00:52:39.529 been in the conventional care arm,
NOTE Confidence: 0.812096425714286
00:52:39.530 --> 00:52:41.756 but 44 crossed over to MMA.
NOTE Confidence: 0.812096425714286
00:52:41.760 --> 00:52:42.514 Of those,
NOTE Confidence: 0.812096425714286
00:52:42.514 --> 00:52:44.399 4440 did get to allergenic
NOTE Confidence: 0.812096425714286
00:52:44.399 --> 00:52:45.530 stem cell transplant,
NOTE Confidence: 0.812096425714286
00:52:45.530 --> 00:52:48.392 and 38 were protocol and were
NOTE Confidence: 0.812096425714286
00:52:48.392 --> 00:52:50.300 eligible for protocol analysis.
NOTE Confidence: 0.812096425714286
00:52:50.300 --> 00:52:50.970 I'm interested,
NOTE Confidence: 0.812096425714286
00:52:50.970 --> 00:52:53.315 I'm trying to run through this past.
NOTE Confidence: 0.812096425714286
00:52:53.320 --> 00:52:55.804 The median age is about in the mid 60s.
NOTE Confidence: 0.812096425714286
00:52:55.810 --> 00:52:57.218 We had favorable intermediate
NOTE Confidence: 0.812096425714286

00:52:57.218 --> 00:52:58.274 and adverse risk.
NOTE Confidence: 0.812096425714286

00:52:58.280 --> 00:53:00.256 It included primary induction
NOTE Confidence: 0.812096425714286

00:53:00.256 --> 00:53:01.738 failure earlier relapse,
NOTE Confidence: 0.812096425714286

00:53:01.740 --> 00:53:02.053 relapse,
NOTE Confidence: 0.812096425714286

00:53:02.053 --> 00:53:03.305 refractory second plus relapse
NOTE Confidence: 0.812096425714286

00:53:03.305 --> 00:53:05.192 and I mentioned that with an
NOTE Confidence: 0.812096425714286

00:53:05.192 --> 00:53:06.542 emphasis because those of you
NOTE Confidence: 0.812096425714286

00:53:06.542 --> 00:53:08.210 are familiar with asset trial did
NOTE Confidence: 0.812096425714286

00:53:08.210 --> 00:53:09.560 not include later relapses and
NOTE Confidence: 0.812096425714286

00:53:09.560 --> 00:53:11.164 only with their earlier relapses,
NOTE Confidence: 0.812096425714286

00:53:11.164 --> 00:53:13.943 all of them at about 3 lines
NOTE Confidence: 0.812096425714286

00:53:13.943 --> 00:53:15.800 of medium therapies,
NOTE Confidence: 0.812096425714286

00:53:15.800 --> 00:53:18.100 people had already exhausted
NOTE Confidence: 0.812096425714286

00:53:18.100 --> 00:53:19.250 targeted therapies.
NOTE Confidence: 0.812096425714286

00:53:19.250 --> 00:53:20.984 About 60% of the patient actually
NOTE Confidence: 0.812096425714286

00:53:20.984 --> 00:53:22.931 had a KPS score performance score

NOTE Confidence: 0.812096425714286
00:53:22.931 --> 00:53:24.858 less than 90% and the matter
NOTE Confidence: 0.812096425714286
00:53:24.858 --> 00:53:26.514 presented and the matter of last
NOTE Confidence: 0.812096425714286
00:53:26.514 --> 00:53:28.594 percentage was around 30% and 28%
NOTE Confidence: 0.812096425714286
00:53:28.594 --> 00:53:31.304 which is significantly high truly
NOTE Confidence: 0.812096425714286
00:53:31.304 --> 00:53:33.910 reflecting active disease population.
NOTE Confidence: 0.812096425714286
00:53:33.910 --> 00:53:35.674 And I'm here are the doses that
NOTE Confidence: 0.812096425714286
00:53:35.674 --> 00:53:36.430 are being presented,
NOTE Confidence: 0.812096425714286
00:53:36.430 --> 00:53:39.130 whether you got amab or crossover
NOTE Confidence: 0.812096425714286
00:53:39.130 --> 00:53:41.548 doses of the matter was about
NOTE Confidence: 0.812096425714286
00:53:41.550 --> 00:53:44.166 1616 Gray here where the divided
NOTE Confidence: 0.812096425714286
00:53:44.170 --> 00:53:46.504 the crossover time to UTC from
NOTE Confidence: 0.812096425714286
00:53:46.504 --> 00:53:48.490 the randomization was 29 days.
NOTE Confidence: 0.812096425714286
00:53:48.490 --> 00:53:50.152 With the standard of care on
NOTE Confidence: 0.812096425714286
00:53:50.152 --> 00:53:51.789 the median time was 66 days.
NOTE Confidence: 0.812096425714286
00:53:51.790 --> 00:53:53.704 In the crossover arm the median
NOTE Confidence: 0.812096425714286

00:53:53.704 --> 00:53:54.980 days was 61 days.
NOTE Confidence: 0.7668775975

00:53:54.980 --> 00:53:56.124 Engraftment was very good.
NOTE Confidence: 0.7668775975

00:53:56.124 --> 00:53:57.840 The median time was 14 days
NOTE Confidence: 0.7668775975

00:53:57.899 --> 00:53:59.777 which is what we normally see
NOTE Confidence: 0.7668775975

00:53:59.777 --> 00:54:01.029 with our standard transplant.
NOTE Confidence: 0.7668775975

00:54:01.030 --> 00:54:03.025 Somewhere around there for platelet
NOTE Confidence: 0.7668775975

00:54:03.025 --> 00:54:05.811 was about 19 days and the standard
NOTE Confidence: 0.7668775975

00:54:05.811 --> 00:54:08.310 HCT the kind of matching up nicely
NOTE Confidence: 0.7668775975

00:54:08.310 --> 00:54:11.389 and the comorbidity index as I was
NOTE Confidence: 0.7668775975

00:54:11.389 --> 00:54:13.153 showing here approximately 5050.
NOTE Confidence: 0.7668775975

00:54:13.160 --> 00:54:16.590 When when you look at durable yards.
NOTE Confidence: 0.7668775975

00:54:16.590 --> 00:54:18.132 Here's the number.
NOTE Confidence: 0.7668775975

00:54:18.132 --> 00:54:20.400 About 22% of the patients that I
NOTE Confidence: 0.7668775975

00:54:20.400 --> 00:54:22.422 had durable CR on the study endpoint
NOTE Confidence: 0.7668775975

00:54:22.422 --> 00:54:24.227 versus none in the conventional
NOTE Confidence: 0.7668775975

00:54:24.227 --> 00:54:26.160 curriculum in the crossover arm,

NOTE Confidence: 0.7668775975

00:54:26.160 --> 00:54:27.968 91% received transplant with

NOTE Confidence: 0.7668775975

00:54:27.968 --> 00:54:31.410 52% of those receiving CR CR.

NOTE Confidence: 0.7668775975

00:54:31.410 --> 00:54:34.050 Posted city maintenance with the TK,

NOTE Confidence: 0.7668775975

00:54:34.050 --> 00:54:35.744 I was only allowed for a more

NOTE Confidence: 0.7668775975

00:54:35.744 --> 00:54:37.030 patient with three mutations,

NOTE Confidence: 0.7668775975

00:54:37.030 --> 00:54:38.702 those toward BCR able

NOTE Confidence: 0.7668775975

00:54:38.702 --> 00:54:39.956 TRANSLOCATIONS that screening.

NOTE Confidence: 0.704628711428571

00:54:42.150 --> 00:54:45.524 And these are the the survival cost.

NOTE Confidence: 0.704628711428571

00:54:45.530 --> 00:54:47.866 The oral survival was doubled with Irma Bomb.

NOTE Confidence: 0.704628711428571

00:54:47.870 --> 00:54:50.454 It was 6.4 months compared to 3.2 months.

NOTE Confidence: 0.704628711428571

00:54:50.454 --> 00:54:52.626 One year survival was almost doubled,

NOTE Confidence: 0.704628711428571

00:54:52.630 --> 00:54:55.930 26 months was 13 months.

NOTE Confidence: 0.704628711428571

00:54:55.930 --> 00:54:57.810 In the crossover covert showing,

NOTE Confidence: 0.704628711428571

00:54:57.810 --> 00:55:00.603 the blue line was about 7.1 month and

NOTE Confidence: 0.704628711428571

00:55:00.603 --> 00:55:04.840 the survival there was about 3535.8%.

NOTE Confidence: 0.704628711428571

00:55:04.840 --> 00:55:07.970 First, sorry.
NOTE Confidence: 0.704628711428571

00:55:07.970 --> 00:55:09.894 Forest plots essentially showing
NOTE Confidence: 0.704628711428571

00:55:09.894 --> 00:55:12.299 hazard ratios was applicable across
NOTE Confidence: 0.704628711428571

00:55:12.299 --> 00:55:16.160 most group except the KPS of 9200.
NOTE Confidence: 0.704628711428571

00:55:16.160 --> 00:55:18.890 I relapsed. Refractory now those are
NOTE Confidence: 0.704628711428571

00:55:18.890 --> 00:55:22.180 the ones where they crossed the line.
NOTE Confidence: 0.704628711428571

00:55:22.180 --> 00:55:24.021 And and when you look at evently
NOTE Confidence: 0.704628711428571

00:55:24.021 --> 00:55:25.620 survival and intent to trade group,
NOTE Confidence: 0.704628711428571

00:55:25.620 --> 00:55:30.380 I'm at a better rate of 28% of 0.2%.
NOTE Confidence: 0.704628711428571

00:55:30.380 --> 00:55:32.020 Specifically, when you follow these
NOTE Confidence: 0.704628711428571

00:55:32.020 --> 00:55:33.660 patients for long term survival,
NOTE Confidence: 0.704628711428571

00:55:33.660 --> 00:55:35.480 six months survival is 100%,
NOTE Confidence: 0.704628711428571

00:55:35.480 --> 00:55:37.064 twelve months, 92 percent,
NOTE Confidence: 0.704628711428571

00:55:37.064 --> 00:55:39.400 18 months 71% are two years.
NOTE Confidence: 0.704628711428571

00:55:39.400 --> 00:55:42.005 Almost 60% of the patients that had
NOTE Confidence: 0.704628711428571

00:55:42.005 --> 00:55:43.840 remission were alive and ongoing.

NOTE Confidence: 0.704628711428571
00:55:43.840 --> 00:55:45.646 Here are some of the adverse events.
NOTE Confidence: 0.704628711428571
00:55:45.650 --> 00:55:46.690 As you can see here,
NOTE Confidence: 0.704628711428571
00:55:46.690 --> 00:55:48.951 we were anticipating a high dose of
NOTE Confidence: 0.704628711428571
00:55:48.951 --> 00:55:50.660 chemotherapy might cause problems and
NOTE Confidence: 0.704628711428571
00:55:50.660 --> 00:55:53.047 neutropenia was on similar rates both sides.
NOTE Confidence: 0.704628711428571
00:55:53.050 --> 00:55:54.370 The mucositis was almost
NOTE Confidence: 0.704628711428571
00:55:54.370 --> 00:55:55.690 similar on both sides.
NOTE Confidence: 0.704628711428571
00:55:55.690 --> 00:55:58.634 The rates of GVHD was not really different,
NOTE Confidence: 0.704628711428571
00:55:58.640 --> 00:56:02.430 but sepsis was lower in the conventional
NOTE Confidence: 0.704628711428571
00:56:02.430 --> 00:56:05.350 compared to conventional now.
NOTE Confidence: 0.704628711428571
00:56:05.350 --> 00:56:06.175 So in summary,
NOTE Confidence: 0.704628711428571
00:56:06.175 --> 00:56:07.550 in patients greater than 55
NOTE Confidence: 0.704628711428571
00:56:07.550 --> 00:56:08.930 years with active disease,
NOTE Confidence: 0.704628711428571
00:56:08.930 --> 00:56:12.122 I'm not followed immediately by reduced
NOTE Confidence: 0.704628711428571
00:56:12.122 --> 00:56:14.312 intensity transplant in his population
NOTE Confidence: 0.704628711428571

00:56:14.312 --> 00:56:16.182 that's typically not transplant eligible

NOTE Confidence: 0.704628711428571

00:56:16.182 --> 00:56:18.550 is now made feasible and possible.

NOTE Confidence: 0.704628711428571

00:56:18.550 --> 00:56:20.512 As a result of the study I am having

NOTE Confidence: 0.704628711428571

00:56:20.512 --> 00:56:22.253 general was well tolerated and resulted

NOTE Confidence: 0.704628711428571

00:56:22.253 --> 00:56:24.170 in engraftment in all those patients

NOTE Confidence: 0.704628711428571

00:56:24.170 --> 00:56:26.186 and had a high rate of durable CR

NOTE Confidence: 0.704628711428571

00:56:26.186 --> 00:56:27.568 lasting greater than six months.

NOTE Confidence: 0.704628711428571

00:56:27.570 --> 00:56:29.334 And for those who have CR lasting

NOTE Confidence: 0.704628711428571

00:56:29.334 --> 00:56:31.270 more than six months about 60% of

NOTE Confidence: 0.704628711428571

00:56:31.270 --> 00:56:33.350 our life on the long run the rates

NOTE Confidence: 0.704628711428571

00:56:33.350 --> 00:56:35.898 of serious adverse events were small.

NOTE Confidence: 0.704628711428571

00:56:35.900 --> 00:56:37.892 I am at office of very normal solution

NOTE Confidence: 0.704628711428571

00:56:37.892 --> 00:56:39.373 to increase access to transplant

NOTE Confidence: 0.704628711428571

00:56:39.373 --> 00:56:40.918 and improve outcomes in patients

NOTE Confidence: 0.704628711428571

00:56:40.918 --> 00:56:42.789 that are relapsed and refractory.

NOTE Confidence: 0.704628711428571

00:56:42.790 --> 00:56:43.304 You know,

NOTE Confidence: 0.704628711428571
00:56:43.304 --> 00:56:45.590 I have two more slides and I'm going to,
NOTE Confidence: 0.704628711428571
00:56:45.590 --> 00:56:47.550 I'm going to wind up with that.
NOTE Confidence: 0.704628711428571
00:56:47.550 --> 00:56:50.174 Some of you who were at Ash probably
NOTE Confidence: 0.704628711428571
00:56:50.174 --> 00:56:52.520 heard of this trial ASAP trial,
NOTE Confidence: 0.704628711428571
00:56:52.520 --> 00:56:54.888 which is kind of trying to gain access
NOTE Confidence: 0.704628711428571
00:56:54.888 --> 00:56:56.734 for alternate transplant for those
NOTE Confidence: 0.704628711428571
00:56:56.734 --> 00:56:58.724 who have primary induction failure,
NOTE Confidence: 0.704628711428571
00:56:58.730 --> 00:57:00.865 trying to make a case saying that,
NOTE Confidence: 0.704628711428571
00:57:00.870 --> 00:57:03.354 you know the need for further
NOTE Confidence: 0.704628711428571
00:57:03.354 --> 00:57:04.596 intensification chemotherapy to
NOTE Confidence: 0.704628711428571
00:57:04.596 --> 00:57:06.622 achieve CR is perhaps not needed as
NOTE Confidence: 0.704628711428571
00:57:06.622 --> 00:57:08.496 long as you can sequentially give
NOTE Confidence: 0.704628711428571
00:57:08.496 --> 00:57:10.836 chemotherapy and take them to transplant
NOTE Confidence: 0.704628711428571
00:57:10.836 --> 00:57:12.776 if you have a donor available.
NOTE Confidence: 0.704628711428571
00:57:12.776 --> 00:57:15.114 Thereby the kind of trying to show that
NOTE Confidence: 0.704628711428571

00:57:15.114 --> 00:57:16.752 you probably don't need to achieve
NOTE Confidence: 0.704628711428571

00:57:16.752 --> 00:57:18.987 CR if you have a donor availability.
NOTE Confidence: 0.704628711428571

00:57:18.990 --> 00:57:20.694 But some of the practices in that study
NOTE Confidence: 0.704628711428571

00:57:20.694 --> 00:57:22.690 might not be applicable in the United States.
NOTE Confidence: 0.704628711428571

00:57:22.690 --> 00:57:24.286 But for the purposes of discussion
NOTE Confidence: 0.704628711428571

00:57:24.286 --> 00:57:25.350 I've left it here.
NOTE Confidence: 0.704628711428571

00:57:25.350 --> 00:57:27.190 But I would end my talk by summarizing
NOTE Confidence: 0.704628711428571

00:57:27.190 --> 00:57:29.268 this for those of you who are interested.
NOTE Confidence: 0.704628711428571

00:57:29.270 --> 00:57:31.825 Since ARMA but ASAP are now trying
NOTE Confidence: 0.704628711428571

00:57:31.825 --> 00:57:34.465 to advance transplant in the context
NOTE Confidence: 0.704628711428571

00:57:34.465 --> 00:57:36.285 of relapse refractory study,
NOTE Confidence: 0.704628711428571

00:57:36.290 --> 00:57:38.010 let's let's see what they both talked about.
NOTE Confidence: 0.704628711428571

00:57:38.010 --> 00:57:39.910 ASAP Trap was predominantly looking
NOTE Confidence: 0.704628711428571

00:57:39.910 --> 00:57:41.810 into fit early relapsed patients
NOTE Confidence: 0.695595272142857

00:57:41.870 --> 00:57:43.378 that was primary induction.
NOTE Confidence: 0.695595272142857

00:57:43.380 --> 00:57:44.943 They're faster laps.

NOTE Confidence: 0.695595272142857

00:57:44.943 --> 00:57:47.548 It uses intensive sequential conditioning.

NOTE Confidence: 0.695595272142857

00:57:47.550 --> 00:57:49.290 Our chemotherapy rather followed by

NOTE Confidence: 0.695595272142857

00:57:49.290 --> 00:57:50.682 transplant preparation regimen which

NOTE Confidence: 0.695595272142857

00:57:50.682 --> 00:57:52.470 is blumel TB in an eighth grade.

NOTE Confidence: 0.695595272142857

00:57:52.470 --> 00:57:54.144 The flip side to that is one of the

NOTE Confidence: 0.695595272142857

00:57:54.144 --> 00:57:56.130 novel therapies that we used to treat

NOTE Confidence: 0.695595272142857

00:57:56.130 --> 00:57:57.710 relapsed refractory leukemia was allowed.

NOTE Confidence: 0.695595272142857

00:57:57.710 --> 00:57:59.862 So you can argue maybe that's not suitable

NOTE Confidence: 0.695595272142857

00:57:59.862 --> 00:58:01.448 for practicing in the United States.

NOTE Confidence: 0.695595272142857

00:58:01.450 --> 00:58:03.682 And even then if you know when we've

NOTE Confidence: 0.695595272142857

00:58:03.682 --> 00:58:05.831 known in the past that we use repeated

NOTE Confidence: 0.695595272142857

00:58:05.831 --> 00:58:06.955 chemotherapy for labs refractory

NOTE Confidence: 0.695595272142857

00:58:06.955 --> 00:58:09.107 disease to make them get into see how

NOTE Confidence: 0.695595272142857

00:58:09.107 --> 00:58:10.511 to get the transparent perhaps that's

NOTE Confidence: 0.695595272142857

00:58:10.511 --> 00:58:12.444 only about 15 to 20% of the patients.

NOTE Confidence: 0.695595272142857

00:58:12.444 --> 00:58:14.472 We think that might impact even
NOTE Confidence: 0.695595272142857

00:58:14.472 --> 00:58:17.210 if you are if you decide to give a
NOTE Confidence: 0.695595272142857

00:58:17.210 --> 00:58:18.875 sequential therapy maybe about 700
NOTE Confidence: 0.695595272142857

00:58:18.875 --> 00:58:21.047 to 1000 patients as you're Gerald
NOTE Confidence: 0.695595272142857

00:58:21.047 --> 00:58:22.906 summarized it beautifully and may
NOTE Confidence: 0.695595272142857

00:58:22.906 --> 00:58:24.686 be eligible to become transparent
NOTE Confidence: 0.695595272142857

00:58:24.686 --> 00:58:26.628 using that intensive chemo approach.
NOTE Confidence: 0.695595272142857

00:58:26.628 --> 00:58:27.496 In contrast,
NOTE Confidence: 0.695595272142857

00:58:27.496 --> 00:58:30.100 Sierra included fit or unfit patients
NOTE Confidence: 0.695595272142857

00:58:30.100 --> 00:58:31.876 both with primary induction failure or
NOTE Confidence: 0.695595272142857

00:58:31.876 --> 00:58:33.618 first relapse who have traditionally
NOTE Confidence: 0.695595272142857

00:58:33.618 --> 00:58:35.638 been considered transplant ineligible.
NOTE Confidence: 0.695595272142857

00:58:35.640 --> 00:58:39.666 And also included second of later.
NOTE Confidence: 0.695595272142857

00:58:39.670 --> 00:58:41.546 Encompassing a extensively relapse
NOTE Confidence: 0.695595272142857

00:58:41.546 --> 00:58:43.891 cases including those who are
NOTE Confidence: 0.695595272142857

00:58:43.891 --> 00:58:46.302 relapsed with contemporary available

NOTE Confidence: 0.695595272142857
00:58:46.302 --> 00:58:48.178 medications but most people might
NOTE Confidence: 0.695595272142857
00:58:48.178 --> 00:58:50.050 have gone into palliative care are
NOTE Confidence: 0.695595272142857
00:58:50.113 --> 00:58:51.966 now getting eligible to consider
NOTE Confidence: 0.695595272142857
00:58:51.966 --> 00:58:53.806 as an extension of transplant.
NOTE Confidence: 0.695595272142857
00:58:53.810 --> 00:58:55.850 And I think as as Doctor Gerard mentioned
NOTE Confidence: 0.695595272142857
00:58:55.850 --> 00:58:57.973 he thinks with this concept approximately
NOTE Confidence: 0.695595272142857
00:58:57.973 --> 00:58:59.923 8000 patients who were historically
NOTE Confidence: 0.695595272142857
00:58:59.923 --> 00:59:01.327 considered not transparent eligible
NOTE Confidence: 0.695595272142857
00:59:01.327 --> 00:59:03.247 may be eligible for other transplant
NOTE Confidence: 0.695595272142857
00:59:03.247 --> 00:59:05.570 if you have a donor ready and be available.
NOTE Confidence: 0.695595272142857
00:59:05.570 --> 00:59:08.242 And I posted this drug being explored for
NOTE Confidence: 0.695595272142857
00:59:08.242 --> 00:59:10.189 different donors conditioning regimen.
NOTE Confidence: 0.695595272142857
00:59:10.190 --> 00:59:12.030 Both in a hematologic,
NOTE Confidence: 0.695595272142857
00:59:12.030 --> 00:59:13.870 both neoplastic and non
NOTE Confidence: 0.695595272142857
00:59:13.870 --> 00:59:14.790 neoplastic conditions.
NOTE Confidence: 0.695595272142857

00:59:14.790 --> 00:59:16.309 Going forwards with that I'm going to
NOTE Confidence: 0.695595272142857

00:59:16.309 --> 00:59:18.088 invest and thank you all for your attention.
NOTE Confidence: 0.695595272142857

00:59:18.090 --> 00:59:19.770 I'll open up the platform provider questions.
NOTE Confidence: 0.695595272142857

00:59:19.770 --> 00:59:20.378 Thank you so much.
NOTE Confidence: 0.6043139125

00:59:29.850 --> 00:59:32.138 You muted Stewart. Sorry.
NOTE Confidence: 0.593766986666667

00:59:32.190 --> 00:59:35.298 Thanks. Thanks, Louis.
NOTE Confidence: 0.593766986666667

00:59:35.300 --> 00:59:37.397 So we have just a few minutes to field
NOTE Confidence: 0.593766986666667

00:59:37.397 --> 00:59:39.580 some questions if people want to submit.
NOTE Confidence: 0.593766986666667

00:59:39.580 --> 00:59:41.668 I'll just start with a quick one that
NOTE Confidence: 0.593766986666667

00:59:41.668 --> 00:59:43.506 came through the chat that we couldn't
NOTE Confidence: 0.593766986666667

00:59:43.506 --> 00:59:45.759 respond to and this is for Doctor Sophie,
NOTE Confidence: 0.593766986666667

00:59:45.760 --> 00:59:48.912 can you just comment on the use of
NOTE Confidence: 0.593766986666667

00:59:48.912 --> 00:59:50.940 corticosteroids and card T patients?
NOTE Confidence: 0.593766986666667

00:59:50.940 --> 00:59:51.993 Are these allowed?
NOTE Confidence: 0.593766986666667

00:59:51.993 --> 00:59:53.397 Do they impact therapy?
NOTE Confidence: 0.593766986666667

00:59:53.400 --> 00:59:56.240 On paraphrasing the question,

NOTE Confidence: 0.593766986666667
00:59:56.240 --> 00:59:57.895 but the question was really
NOTE Confidence: 0.593766986666667
00:59:57.895 --> 01:00:00.066 what is the impact of using
NOTE Confidence: 0.593766986666667
01:00:00.066 --> 01:00:01.850 steroids in these patients?
NOTE Confidence: 0.825889062142857
01:00:02.790 --> 01:00:05.470 Yeah. So we generally try to limit the
NOTE Confidence: 0.825889062142857
01:00:05.470 --> 01:00:08.749 use of steroids before cartee collection.
NOTE Confidence: 0.825889062142857
01:00:08.750 --> 01:00:11.134 It's it's critical that they have at least.
NOTE Confidence: 0.735509422
01:00:13.470 --> 01:00:16.190 One week window before Cartee.
NOTE Confidence: 0.735509422
01:00:16.190 --> 01:00:18.830 We do know that steroids are very lympho
NOTE Confidence: 0.735509422
01:00:18.830 --> 01:00:20.867 depleting and the early postpartum
NOTE Confidence: 0.735509422
01:00:20.867 --> 01:00:23.047 period when they developed toxicity.
NOTE Confidence: 0.735509422
01:00:23.050 --> 01:00:25.612 Though it has been shown that giving
NOTE Confidence: 0.735509422
01:00:25.612 --> 01:00:28.623 a short course of either steroids or
NOTE Confidence: 0.735509422
01:00:28.623 --> 01:00:30.918 other antibodies like tocilizumab to
NOTE Confidence: 0.735509422
01:00:30.918 --> 01:00:33.849 treat cytokine release syndrome or
NOTE Confidence: 0.735509422
01:00:33.849 --> 01:00:36.262 neurologic toxicities does not impact
NOTE Confidence: 0.735509422

01:00:36.262 --> 01:00:39.090 the long term outcome of these patients.

NOTE Confidence: 0.735509422

01:00:39.090 --> 01:00:42.936 But again the steroid tapers are.

NOTE Confidence: 0.735509422

01:00:42.940 --> 01:00:44.935 Rather quick, typically less than a week.

NOTE Confidence: 0.846978154210526

01:00:48.750 --> 01:00:52.198 OK, thanks. And I see one other one

NOTE Confidence: 0.846978154210526

01:00:52.198 --> 01:00:55.064 other question in the chat from

NOTE Confidence: 0.846978154210526

01:00:55.064 --> 01:00:57.459 Doctor Zeiden and that's regards.

NOTE Confidence: 0.846978154210526

01:00:57.460 --> 01:01:00.622 The whole issue of remission status

NOTE Confidence: 0.846978154210526

01:01:00.622 --> 01:01:04.362 prior to transplant and asking if in

NOTE Confidence: 0.846978154210526

01:01:04.362 --> 01:01:07.740 the ISOMAP study was there a need to

NOTE Confidence: 0.846978154210526

01:01:07.740 --> 01:01:09.500 document CR before the transplant.

NOTE Confidence: 0.846978154210526

01:01:09.500 --> 01:01:11.460 So is the short answer is no.

NOTE Confidence: 0.846978154210526

01:01:11.460 --> 01:01:14.624 iMac was part of the transplant conditioning.

NOTE Confidence: 0.846978154210526

01:01:14.630 --> 01:01:16.820 So these are people who relapse,

NOTE Confidence: 0.846978154210526

01:01:16.820 --> 01:01:18.935 refractory disease had bone marrows

NOTE Confidence: 0.846978154210526

01:01:18.935 --> 01:01:22.022 with an average of 30% blasts who

NOTE Confidence: 0.846978154210526

01:01:22.022 --> 01:01:25.270 instead of our paradigm of going to

NOTE Confidence: 0.846978154210526
01:01:25.367 --> 01:01:28.014 salvage therapy and requiring remission
NOTE Confidence: 0.846978154210526
01:01:28.014 --> 01:01:31.310 that was the that was the control arm.
NOTE Confidence: 0.846978154210526
01:01:31.310 --> 01:01:33.410 They just went right to the transplant.
NOTE Confidence: 0.846978154210526
01:01:33.410 --> 01:01:35.240 So they got the therapeutic dose
NOTE Confidence: 0.846978154210526
01:01:35.240 --> 01:01:37.835 and the the 12 days before the
NOTE Confidence: 0.846978154210526
01:01:37.835 --> 01:01:39.579 transplant and that's ablative.
NOTE Confidence: 0.846978154210526
01:01:39.580 --> 01:01:41.776 So there's no doing a bone marrow to look.
NOTE Confidence: 0.846978154210526
01:01:41.780 --> 01:01:44.606 You saw the average delivery of
NOTE Confidence: 0.846978154210526
01:01:44.606 --> 01:01:47.020 radiation there was 16 Gray,
NOTE Confidence: 0.846978154210526
01:01:47.020 --> 01:01:49.358 that's about 3 to 4 Gray higher
NOTE Confidence: 0.846978154210526
01:01:49.358 --> 01:01:51.089 total body radiation dose that
NOTE Confidence: 0.846978154210526
01:01:51.089 --> 01:01:53.063 we can safely give any patient.
NOTE Confidence: 0.846978154210526
01:01:53.070 --> 01:01:56.148 So this is a very ablative
NOTE Confidence: 0.846978154210526
01:01:56.150 --> 01:01:59.138 dose of radiotherapy.
NOTE Confidence: 0.846978154210526
01:01:59.140 --> 01:02:01.835 And and then marrows are not done
NOTE Confidence: 0.846978154210526

01:02:01.835 --> 01:02:04.240 prior to delivering the transplant you
NOTE Confidence: 0.846978154210526

01:02:04.240 --> 01:02:06.984 have to rescue the patient with the
NOTE Confidence: 0.846978154210526

01:02:07.061 --> 01:02:09.372 graft and the high CR rate confirms
NOTE Confidence: 0.846978154210526

01:02:09.372 --> 01:02:11.904 the efficacy of of that agent.
NOTE Confidence: 0.809493941666667

01:02:14.780 --> 01:02:16.028 I think how much? How much?
NOTE Confidence: 0.763167

01:02:17.830 --> 01:02:20.579 So in Americas asking about acquiring
NOTE Confidence: 0.763167

01:02:20.579 --> 01:02:23.230 CR in one arm and not the other,
NOTE Confidence: 0.763167

01:02:23.230 --> 01:02:26.849 so the other arm was to choose
NOTE Confidence: 0.763167

01:02:26.849 --> 01:02:28.530 conventional treatment, you're right.
NOTE Confidence: 0.763167

01:02:28.530 --> 01:02:29.810 And then those patients
NOTE Confidence: 0.763167

01:02:29.810 --> 01:02:31.090 don't go to transplant.
NOTE Confidence: 0.763167

01:02:31.090 --> 01:02:36.456 Remember this is a a group restricted age 55.
NOTE Confidence: 0.763167

01:02:36.456 --> 01:02:39.824 And we don't have,
NOTE Confidence: 0.763167

01:02:39.830 --> 01:02:41.769 if you're referring to the ASAP study,
NOTE Confidence: 0.763167

01:02:41.770 --> 01:02:44.488 we don't have flame PSA regimen,
NOTE Confidence: 0.763167

01:02:44.490 --> 01:02:47.250 which is the popular German regimen.

NOTE Confidence: 0.763167

01:02:47.250 --> 01:02:51.234 And if one looks over 40 years of

NOTE Confidence: 0.763167

01:02:51.234 --> 01:02:54.473 evaluations of outcome for allograft

NOTE Confidence: 0.763167

01:02:54.473 --> 01:02:58.038 being the single most predictive.

NOTE Confidence: 0.763167

01:02:58.040 --> 01:02:59.645 Variable for treatment

NOTE Confidence: 0.763167

01:02:59.645 --> 01:03:01.785 failure is disease status.

NOTE Confidence: 0.763167

01:03:01.790 --> 01:03:04.196 It's an increase in blasts in

NOTE Confidence: 0.763167

01:03:04.196 --> 01:03:05.800 the marrow pre transplant.

NOTE Confidence: 0.763167

01:03:05.800 --> 01:03:06.908 So remember these these

NOTE Confidence: 0.763167

01:03:06.908 --> 01:03:08.016 were people with actively.

NOTE Confidence: 0.763167

01:03:08.020 --> 01:03:09.670 These weren't people with just

NOTE Confidence: 0.763167

01:03:09.670 --> 01:03:12.700 6% blasts in their marrow.

NOTE Confidence: 0.763167

01:03:12.700 --> 01:03:14.239 So they, they,

NOTE Confidence: 0.763167

01:03:14.239 --> 01:03:17.317 they were allowed to to crossover,

NOTE Confidence: 0.763167

01:03:17.320 --> 01:03:19.354 but these are people who are

NOTE Confidence: 0.763167

01:03:19.354 --> 01:03:21.202 conventionally don't go to transplant

NOTE Confidence: 0.763167

01:03:21.202 --> 01:03:23.357 around around the world really,
NOTE Confidence: 0.763167

01:03:23.360 --> 01:03:24.835 unless they're on a clinical
NOTE Confidence: 0.763167

01:03:24.835 --> 01:03:26.310 trial like that German study.
NOTE Confidence: 0.762104

01:03:27.890 --> 01:03:29.430 There's actually an excellent review,
NOTE Confidence: 0.762104

01:03:29.430 --> 01:03:31.218 but Zeidan armor and Dan Polia
NOTE Confidence: 0.762104

01:03:31.218 --> 01:03:33.139 Dan Polio about even the need
NOTE Confidence: 0.762104

01:03:33.139 --> 01:03:34.809 for CR after induction therapy.
NOTE Confidence: 0.762104

01:03:34.810 --> 01:03:36.530 I'm sure Rama can extrapolate
NOTE Confidence: 0.762104

01:03:36.530 --> 01:03:38.250 that into labs refractory setting.
NOTE Confidence: 0.762104

01:03:38.250 --> 01:03:40.105 How CR one came into the foreplay,
NOTE Confidence: 0.762104

01:03:40.110 --> 01:03:41.286 whether it's of essence.
NOTE Confidence: 0.762104

01:03:41.286 --> 01:03:43.499 I'll refer him back to his own
NOTE Confidence: 0.762104

01:03:43.499 --> 01:03:45.202 publication with that which tells you
NOTE Confidence: 0.762104

01:03:45.202 --> 01:03:47.319 the real utility of CR in modern times.
NOTE Confidence: 0.702696867857143

01:03:49.190 --> 01:03:53.376 Yeah, what's probably a good subject for
NOTE Confidence: 0.702696867857143

01:03:53.376 --> 01:03:56.865 further discussion in our transplant

NOTE Confidence: 0.702696867857143

01:03:56.865 --> 01:04:00.148 leukemia meetings. I I slept see

NOTE Confidence: 0.881636893666667

01:04:00.240 --> 01:04:02.081 guard also just wanted to say that

NOTE Confidence: 0.881636893666667

01:04:02.081 --> 01:04:04.198 this type of therapy is also very

NOTE Confidence: 0.881636893666667

01:04:04.198 --> 01:04:06.106 exciting for other forms of adoptive

NOTE Confidence: 0.881636893666667

01:04:06.171 --> 01:04:08.201 cell therapy because I know that they

NOTE Confidence: 0.881636893666667

01:04:08.201 --> 01:04:10.703 are looking at giving non myeloablative

NOTE Confidence: 0.881636893666667

01:04:10.703 --> 01:04:13.949 doses of this type of radioimmunotherapy

NOTE Confidence: 0.881636893666667

01:04:13.949 --> 01:04:16.795 actually at lower doses rather than

NOTE Confidence: 0.881636893666667

01:04:16.795 --> 01:04:19.025 ablative for patients pre adoptive

NOTE Confidence: 0.881636893666667

01:04:19.100 --> 01:04:21.440 cell therapy and we already have

NOTE Confidence: 0.881636893666667

01:04:21.440 --> 01:04:26.168 data on how radiation might actually.

NOTE Confidence: 0.881636893666667

01:04:26.170 --> 01:04:30.940 Decreased T Reg populations for example,

NOTE Confidence: 0.881636893666667

01:04:30.940 --> 01:04:32.896 and that may be actually important

NOTE Confidence: 0.881636893666667

01:04:32.896 --> 01:04:35.268 in the postcard T setting as well.

NOTE Confidence: 0.725991024444445

01:04:36.830 --> 01:04:39.399 One last question for Doctor Isufi in

NOTE Confidence: 0.725991024444445

01:04:39.399 --> 01:04:42.996 the Q&A, how to choose between car T
NOTE Confidence: 0.725991024444445

01:04:42.996 --> 01:04:45.560 cell therapy or immunotherapy, very,
NOTE Confidence: 0.725991024444445

01:04:45.560 --> 01:04:47.760 very appropriate question not just for
NOTE Confidence: 0.725991024444445

01:04:47.760 --> 01:04:50.098 lymphoma, but iris what do you think?
NOTE Confidence: 0.818039439230769

01:04:50.340 --> 01:04:52.020 Yeah, so I mean I think that's
NOTE Confidence: 0.818039439230769

01:04:52.020 --> 01:04:53.969 a that's a very valid question.
NOTE Confidence: 0.818039439230769

01:04:53.970 --> 01:04:56.454 Unfortunately you know immunotherapy
NOTE Confidence: 0.818039439230769

01:04:56.454 --> 01:05:00.680 in terms of PD1 PDL one access has
NOTE Confidence: 0.818039439230769

01:05:00.680 --> 01:05:04.220 not had very good outcomes in the
NOTE Confidence: 0.818039439230769

01:05:04.220 --> 01:05:06.905 setting of non Hodgkin lymphoma.
NOTE Confidence: 0.818039439230769

01:05:06.910 --> 01:05:11.670 Particularly aggressive lymphoma and so.
NOTE Confidence: 0.818039439230769

01:05:11.670 --> 01:05:13.902 And you know that those particular
NOTE Confidence: 0.818039439230769

01:05:13.902 --> 01:05:16.900 drugs are not are not have very low
NOTE Confidence: 0.818039439230769

01:05:16.900 --> 01:05:19.481 CR rates as single single agents and
NOTE Confidence: 0.818039439230769

01:05:19.481 --> 01:05:21.987 they do not add much to combination.
NOTE Confidence: 0.818039439230769

01:05:21.990 --> 01:05:25.182 So I think a court would be preferred

NOTE Confidence: 0.818039439230769

01:05:25.182 --> 01:05:28.508 in terms of antibody drug conjugates.

NOTE Confidence: 0.818039439230769

01:05:28.510 --> 01:05:30.990 I mean I think that's that's a whole

NOTE Confidence: 0.818039439230769

01:05:30.990 --> 01:05:33.295 other class of drugs that is competing

NOTE Confidence: 0.818039439230769

01:05:33.295 --> 01:05:36.224 with car T cell therapy in all fronts

NOTE Confidence: 0.818039439230769

01:05:36.224 --> 01:05:37.884 including non Hodgkin lymphoma,

NOTE Confidence: 0.818039439230769

01:05:37.890 --> 01:05:41.054 AML and multiple myeloma and I think

NOTE Confidence: 0.818039439230769

01:05:41.054 --> 01:05:44.438 we have to look at the targets.

NOTE Confidence: 0.818039439230769

01:05:44.440 --> 01:05:47.128 To make sure that when we give these

NOTE Confidence: 0.818039439230769

01:05:47.128 --> 01:05:48.987 therapies the patients retain the

NOTE Confidence: 0.818039439230769

01:05:48.987 --> 01:05:51.577 target and and how to sequence them

NOTE Confidence: 0.818039439230769

01:05:51.650 --> 01:05:53.960 is actually a matter of very hot

NOTE Confidence: 0.818039439230769

01:05:53.960 --> 01:05:56.240 debate and ongoing trials right now,

NOTE Confidence: 0.818039439230769

01:05:56.240 --> 01:05:59.924 what the best approach might be

NOTE Confidence: 0.818039439230769

01:05:59.924 --> 01:06:03.280 with these by specifics I know.

NOTE Confidence: 0.818039439230769

01:06:03.280 --> 01:06:06.376 There was another question in the in the Q&A,

NOTE Confidence: 0.818039439230769

01:06:06.380 --> 01:06:10.980 for example for, for.

NOTE Confidence: 0.818039439230769

01:06:10.980 --> 01:06:14.940 For leukemia in patients who for

NOTE Confidence: 0.818039439230769

01:06:14.940 --> 01:06:17.580 example receive blinatumomab precarity

NOTE Confidence: 0.818039439230769

01:06:17.580 --> 01:06:20.380 you know how do those patients fare

NOTE Confidence: 0.818039439230769

01:06:20.380 --> 01:06:23.258 and that because both of those are

NOTE Confidence: 0.818039439230769

01:06:23.258 --> 01:06:25.658 city 19 targeting therapies and so

NOTE Confidence: 0.818039439230769

01:06:25.660 --> 01:06:28.100 sequencing is very important there.

NOTE Confidence: 0.818039439230769

01:06:28.100 --> 01:06:30.206 And the interpretation of of the

NOTE Confidence: 0.818039439230769

01:06:30.206 --> 01:06:33.666 data so far is that if they have a

NOTE Confidence: 0.818039439230769

01:06:33.666 --> 01:06:35.646 good response to blinatumomab and

NOTE Confidence: 0.818039439230769

01:06:35.720 --> 01:06:38.096 they maintain their CD 19 status

NOTE Confidence: 0.818039439230769

01:06:38.096 --> 01:06:40.200 pre cartes that they do well.

NOTE Confidence: 0.818039439230769

01:06:40.200 --> 01:06:40.460 However,

NOTE Confidence: 0.818039439230769

01:06:40.460 --> 01:06:42.280 if they do not have a good

NOTE Confidence: 0.818039439230769

01:06:42.348 --> 01:06:43.830 response to blinatumomab,

NOTE Confidence: 0.818039439230769

01:06:43.830 --> 01:06:47.425 they will also respond poorly to
NOTE Confidence: 0.818039439230769

01:06:47.425 --> 01:06:50.095 car T unfortunately that's a high
NOTE Confidence: 0.818039439230769

01:06:50.095 --> 01:06:52.858 risk group and if they lose City
NOTE Confidence: 0.818039439230769

01:06:52.858 --> 01:06:55.387 19 after blina then they actually
NOTE Confidence: 0.818039439230769

01:06:55.387 --> 01:06:58.243 have very poor responses to court.
NOTE Confidence: 0.818039439230769

01:06:58.250 --> 01:07:01.036 So we have to be careful about
NOTE Confidence: 0.818039439230769

01:07:01.036 --> 01:07:03.991 how we we sequence these therapies
NOTE Confidence: 0.818039439230769

01:07:03.991 --> 01:07:06.890 and we have to really monitor.
NOTE Confidence: 0.818039439230769

01:07:06.890 --> 01:07:09.270 I mean I know many academic centers
NOTE Confidence: 0.818039439230769

01:07:09.270 --> 01:07:11.096 now when they look at city.
NOTE Confidence: 0.818039439230769

01:07:11.100 --> 01:07:12.438 19 and C22,
NOTE Confidence: 0.818039439230769

01:07:12.438 --> 01:07:15.114 they do not just report for
NOTE Confidence: 0.818039439230769

01:07:15.114 --> 01:07:18.128 example whether it's dim positive,
NOTE Confidence: 0.818039439230769

01:07:18.130 --> 01:07:18.696 you know,
NOTE Confidence: 0.818039439230769

01:07:18.696 --> 01:07:20.394 or they will actually report a
NOTE Confidence: 0.818039439230769

01:07:20.394 --> 01:07:22.349 number for the level of expression.

NOTE Confidence: 0.818039439230769

01:07:22.350 --> 01:07:24.138 And that becomes very important in

NOTE Confidence: 0.818039439230769

01:07:24.138 --> 01:07:26.722 terms of I know that's what the NCI

NOTE Confidence: 0.818039439230769

01:07:26.722 --> 01:07:28.720 does and that becomes very important

NOTE Confidence: 0.818039439230769

01:07:28.788 --> 01:07:30.748 in terms of what the next therapy

NOTE Confidence: 0.818039439230769

01:07:30.748 --> 01:07:32.470 that they use is going to be.

NOTE Confidence: 0.907274934

01:07:34.360 --> 01:07:36.790 You know if I can add to that

NOTE Confidence: 0.907274934

01:07:36.790 --> 01:07:39.004 comment that you know the nature of

NOTE Confidence: 0.907274934

01:07:39.004 --> 01:07:41.225 drug development was such that we had

NOTE Confidence: 0.907274934

01:07:41.225 --> 01:07:43.234 to go with enabling and then Karti,

NOTE Confidence: 0.907274934

01:07:43.240 --> 01:07:44.920 Karti despite having heavily

NOTE Confidence: 0.907274934

01:07:44.920 --> 01:07:46.600 treated population had highest

NOTE Confidence: 0.907274934

01:07:46.600 --> 01:07:49.038 CR and MRD negative data rates.

NOTE Confidence: 0.907274934

01:07:49.040 --> 01:07:51.146 So that kind of tells you that it's a

NOTE Confidence: 0.907274934

01:07:51.146 --> 01:07:52.826 potential drug just that we may not be

NOTE Confidence: 0.907274934

01:07:52.826 --> 01:07:54.747 able to get it in time whereas other

NOTE Confidence: 0.907274934

01:07:54.747 --> 01:07:56.764 drugs may be dispensing it off the shelf.
NOTE Confidence: 0.907274934

01:07:56.764 --> 01:07:58.004 In terms of the potential,
NOTE Confidence: 0.907274934

01:07:58.010 --> 01:08:00.450 it's clearly there despite a
NOTE Confidence: 0.907274934

01:08:00.450 --> 01:08:02.402 heavily treated population the
NOTE Confidence: 0.907274934

01:08:02.402 --> 01:08:04.767 rates of CR compared to Unism.
NOTE Confidence: 0.907274934

01:08:04.770 --> 01:08:05.481 Under Marty negatively,
NOTE Confidence: 0.907274934

01:08:05.481 --> 01:08:07.388 there is something that we need to look
NOTE Confidence: 0.907274934

01:08:07.388 --> 01:08:08.816 into it if we're looking into that.
NOTE Confidence: 0.886725964285714

01:08:12.320 --> 01:08:14.497 OK. I think we're out of time.
NOTE Confidence: 0.886725964285714

01:08:14.500 --> 01:08:17.476 Thanks, Doctor Sophie and Doctor Garin,
NOTE Confidence: 0.886725964285714

01:08:17.480 --> 01:08:19.940 thanks for all the good questions.
NOTE Confidence: 0.886725964285714

01:08:19.940 --> 01:08:21.984 I hope everybody has a good weekend.
NOTE Confidence: 0.96443205

01:08:23.590 --> 01:08:24.540 Thank you.